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Ayahuasca denotes an Amazonian psychotropic plant tea obtained from Banisteriopsis caapi, 
which contains -carboline alkaloids, chiefly harmine, harmaline and tetrahydroharmine. The tea 
usually incorporates the leaves of Psychotria viridis, which are rich in N,N-dimethyltryptamine 
(DMT), a psychoactive 5-HT2A agonist. The -carbolines reversibly inhibit monoamine-oxidase 
(MAO), effectively preventing oxidative deamination of the orally inactive DMT and allowing 
its absorption and access to the central nervous system. Despite increased use of the tea 
worldwide, easy to perform and validated methods for its characterization do not exist and the 
metabolism and excretion of DMT and the -carbolines has not been studied systematically in 
humans following ayahuasca consumption. Thus, we developed a liquid chromatography–
electrospray ionization-tandem mass spectrometry procedure for the simultaneous quantification 
of the major alkaloid components of ayahuasca, including several known and potential 
metabolites. The assay was applied to a variety of ayahuasca samples and modified to be 
applicable to human blood and urine samples before and after consumption of ayahuasca. The 
major components present in ayahuasca samples were tetrahydroharmine and harmine, followed 
by N,N-dimethyltryptamine and harmaline. The major metabolite of DMT was the corresponding 
N-oxide, DMT-N-oxide which was found in both blood plasma and urine, although not 
detectable in ayahuasca samples. Less than 1% of the administered DMT dose was detected in 
urine or blood plasma, despite the inhibition of monoamine oxidase afforded by the presence of 
the harmala alkaloids in ayahuasca. The major harmala alkaloid excreted was tetrahydroharmine. 
The methods developed would be suitable for the study of ayahuasca in human and 
ethnobotanical research, as well as in forensic examinations of ayahuasca preparations. The 




adequate for use in further toxicological and clinical research on ayahuasca as well as 
functioning as an assay to screen biological samples for endogenous hallucinogens. Based on the 
results of these studies we also present a critical review of 69 published studies reporting the 
detection in human body fluids of three indole alkaloids that possess differing degrees of 
psychedelic activity. Suggestions for the future directions of ayahuasca and endogenous 






















Chapter 1. Introduction 
1.1 Semantics 
N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 
and bufotenine (5-OH-DMT) may be classified generally as chemical derivatives of the mood 
and behavioral modulating essential monoamine neurotransmitter 5-hydroxytrptamine (5-HT or 
serotonin) given that they all share an indole moiety and a basic nitrogen atom connected by an 
alkyl chain. More specifically these molecules may be classified as indoleamine or 
indolealkylamine hallucinogens [1.1]. The word ‘hallucinogen’ has become the most common 
designation in current scientific literature to describe a  variety of substances including psilocybe 
mushrooms, peyote, iboga, bufo alvarius toad venom, and ayahuasca along with their 
corresponding psychoactive compounds psilocybin (4-OH-DMT), mescaline, ibogaine, 5-MeO-
DMT, and DMT, respectively. In addition there are synthetic hallucinogen molecules such as 
lysergic acid diethylamide (LSD-25) and a growing number of other structurally related 
tryptamine and phenethylamine molecules which have been synthesized in laboratories [1.1-.13]. 
Still more hallucinogenic or potentially hallucinogenic compounds have been identified in nearly 
100 species and a wide range of genera and families [1.4].  
When consumed and experienced individually or in combination, as in the case of 
ayahuasca, these hallucinogenic compounds may potentially induce involuntary perceptual 
phenomena (hallucinations) within a conscious and awake organism while in the absence of any 
apparent empirically verifiable externally known stimuli. Terrence McKenna once defined a 
hallucination as being in the presence of that which could previously not be imagined. We may 
call these substances ‘hallucinogens’ because the term has been most commonly used in the 




psychedelic (mind manifesting; Osmond, [1.5]). Other terms such as: psychotomimetic 
(psychosis mimicking; [1.6]), entheogenic (generating the divine; [1.7]), or holotropic [1.8] have 
all generally been used interchangeably with ‘hallucinogen’ depending on a given paradigm or 
context (social or recreational, experimental or therapeutic, religious or mystical, spiritual or 
sacramental). All could possibly be considered misnomers [1.1, 1.9] given that they seem to lack 
the qualitative descriptors necessary to heuristically express the phenomenal possibilities for 
such substances to not only potentially influence perception but also cognition, affect, mood, and 
behavior [1.10. 1.11]. These substances may afford changes in the processing of fundamental 
information regarding the ontology and epistemology of self, emotions, social interactions, 
dependencies, language, as well as the overall integration of conscious, unconscious, 
subconscious, and preconscious information in the brain. This may result in a novel non-ordinary 
‘psychointegrative’ state of consciousness, where limbic system processes may become 
particularly more integrated with neocortical processes [1.1, 1.12]. 
Perhaps a more appropriate distinction for these types of compounds would be as 
‘psychointegrators’ [1.9] which attempts to communicate the holistic and psychodynamic nature  
of the often transpersonal experiences that these compounds may allow for, with potential effects 
upon sensory, behavioral, emotional, and cognitive processes. These substances, such as 
psilocybin, may occasion mystical-type experiences mediating the attribution of substantial and 
sustained personal meaning and spiritual significance [1.13, 1.14]. Perhaps these substances may 
afford a more integrated ontological connection with the quantum-holographic [1.15] to 
cosmological scale unified space-time manifold such as could be described by the schwarzschild 




We may ask the questions: Why do humans produce endogenous psychedelics? Does 
consciousness represent a product or epiphenomenon of the brain? Or does the brain act as a 
tuner directing a certain resolution of awareness to a specific frequency of an omnipresent 
panexperiential consciousness? Could consciousness be a result of an orchestrated objective 
reduction of quantum coherence in brain microtubules [1.17, 1.18]? While this manuscript does 
not claim to answer these questions, future studies of exogenous and endogenous hallucinogens 
could very well lead to clearer empirically testable hypotheses, theories and conclusions. If we 
choose to see these substances, such as ayahuasca, as molecular tools to explore the conscious, 
unconscious and preconscious mind, or as useful neuroscientific and psychological instruments 
to explore novel aspects of the brain and self, we could potentially use them to reveal new 
resolutions of perceived existence and felt experience much like the microscope has done for 
biology or the telescope for astronomy. 
“We do not see the world as it is, we see the world as we are” -the Talmud 
1.2 Historical and social context 
Throughout the thousands of years of recorded and, we may assume, unrecorded history 
and across the entire world, accounts may be found in many religious and mythical texts 
describing what could be called spontaneous or drug induced hallucinogenic, psychointegrative, 
mystical, religious, spiritual, or entheogenic types of experiences. This includes the use of 
‘kykeon’ in the Eleusinian mysteries of ancient Greece [1.19], descriptions in the Rig Veda of 
the use of ‘Soma’ in India [1.20], Mesoamerica’s use of sacred psilocybin mushrooms, Native 
Americans’ use of mescaline-containing Peyote cactus, sacramental use of Iboga among the 
African Bwiti [1.21], Caribbean use of Anadenanthera peregrine seed-based Cohoba snuff 




Pane in 1496, as well as the ongoing use of the synergistically brewed tea Ayahuasca among the 
Amazonians which typically combines the DMT containing leaves of Psychotria viridis with 
MAO inhibiting  harmala beta-carbolines (-carbolines) found in the vines of Banisteriopsis 
caapi [1.10]. The speculative use of ayahuasca has been dated to sometime between A.D. 800 
and 1200 based on the gas chromatography-mass spectrometry (GC-MC) detection of harmine 
alkaloids in ancient Andean hair samples found in northern Chile from an adult male and a one-
year-old baby [1.24]. It has even been speculated that perhaps the biblical Moses, while under 
the MAO inhibiting effects of beta-carbolines found in Peganum harmala (Syrian rue), may have 
had a ‘psychointegrative’ experience when in the presence of, as accounted in the Old 
Testament, the smoke of a burning Acacia bush - which has been found to contain various 
concentrations of DMT [1.25].  
Whether spontaneous or drug-induced, psychointegrative or psychedelic experiences 
have often played vital roles cross-culturally and across history as primary sources of spiritual 
inspiration, inquisitions, oppression, as well as religious participation, potentially providing 
motivation for the institutionalization of many religious sacraments, beliefs, and activities [1.26, 
1.27]. The historical, social, and cross-cultural similarities found in many reports concerning 
various non-ordinary states of consciousness (NOSC) may often represent the probable 
occurrence of a ‘psychointegrative’ phenomenon which could be potentially mediated 
spontaneously by endogenous processes or intentionally by a variety of meditation practices, 
breathing techniques such as pranayama and holotropic breath work [1.28], physical practices 
such as yoga or tantra, fasting, hypnosis techniques, electromagnetic or auditory / visual 
entrainment procedures [1.29], initiation rites or rituals, as well as the therapeutic, recreational, 




substances, which could collectively imply an underlying, potentially endogenous, shared 
neurobiological mechanism of action [1.30]. Thus epistemological claims of supernatural, occult, 
or magical powers, as well as accounts of contact with spirits, angels, demons, deities, gods, 
mythical creatures, the dead, or extraterrestrials which may have been initially acquired through 
psychointegrative or hallucinogenic-related phenomenon may potentially be replaced by 
empirical scientific paradigms evaluating the significance of such subjective experiences, their 
etiology and the biochemical mechanism by which they might be produced and reproduced 
[1.31].  
 Several N,N-dimethylated indolamines have been characterized as endogenous 
hallucinogens in humans and other species. These endogenous hallucinogens have been 
hypothesized to play major roles in diverse phenomena such as sleep and dreaming [1.32], 
reducing anxiety [1.33], near death experiences, out of body experiences, childbirth [1.15, 1.34], 
establishment and maintenance of perceptual homeostasis [1.35], mystical or religious 
experiences [1.13, 1.14, 1.34], psychosis or schizophrenia [136, 1.37], autism, severe depression, 
mania, post-traumatic stress disorder, dissociative disorders, panic disorders, and even UFO 
abduction experiences [1.15, 1.34].  
The first 25 years of scientific research examining endogenous hallucinogens appears to 
be primarily motivated by and limited to psychotomimetic or hallucinogenic paradigms [1.38] 
which propose that the seemingly hallucinatory group of symptoms often associated with the 
heterogeneous psychiatric diagnosis commonly referred to as ‘schizophrenia’ by the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) may actually be a consequence of 
endogenous hallucinogen synthesis leading to the “transmethylation hypothesis of 




decarboxylated to form tryptamine (TA) which could then undergo two methylations using S-
adenosylmethionine (SAMe) as the methyl donor [1.42] to endogenously form the 
hallucinogenic molecule DMT and thus potentially contribute to the symptoms often associated 
with schizophrenia. DMT has hence been identified as a naturally occurring potential product of 
tryptophan metabolism [1.31]. Tryptamine has been identified in the brain [1.43], and the 
enzyme that methylates tryptamine, indole-N-methyltransferase (INMT), was first identified in 
the lungs of rabbits and later in the brain, lung, blood, and cerebral spinal fluid of some 
mammals, including humans [1.43-1.45].  
Certain similarities may potentially be associated between hallucinogen phenomenology 
and endogenous schizophrenia [1.45-1.47]. One study claimed finding a positive correlation 
between urinary DMT and measures of psychotic symptoms in a group of psychotic patients 
[1.48], and while other studies have reported identifying DMT in the blood and urine of certain, 
but not all, patients diagnosed with schizophrenia, DMT was also reported in some normal 
control participants [1.49-1.50]. Many initial reports identifying DMT levels in the body fluids of 
patients diagnosed with schizophrenia have not always been replicated successfully [1.51-1.57] 
given that no statistically significant differences in detectable DMT levels could be found 
between patients diagnosed with schizophrenia relative to control populations, leading to the 
conclusion that if DMT was present it was in too low a concentration to be accurately quantitated 
[1.58].  
Unfortunately, clinical research on all hallucinogens was made more difficult during the 
early 1970’s when the Controlled Substance Act was passed [1.59]. Nevertheless, the biological 
and subjective effects of exogenously administered pharmacological doses of intravenous DMT 




1.62], and the gene encoding for the human INMT enzyme, which catalyzes the final steps of 
endogenous hallucinogenic tryptamine formation, has been isolated, cloned, and transfected into 
mammalian cells [1.63, 1.64]. Northern blot analysis indicated that INMT mRNA transcripts 
were expressed in many human tissues, appearing to be most highly expressed in the lung 
although not appearing in brain. In addition to methylation of indoleamines, the endogenous 
formation of -carbolines from primary tryptamines such as serotonin (5-HT) and 5-
methoxytryptamine has also been suggested [1.65]. Interestingly, pinoline (6-methoxy-THBC) 
which like otherβ-carbolines may inhibit MAO-A [1.66], has been identified by GC/MS to be an 
endogenous component of the pineal gland with similar concentrations and circadian release 
patterns to those of melatonin [1.67], possibly potentiating the effects of endogenous 
hallucinogens by inhibiting the major route of metabolism and potentially mediating phenomena 
such as dreaming [1.32].  This endogenous pinoline / DMT interaction could possibly produce an 
endogenous experience similar to that induced by the consumption of ayahuasca. In this regard, a 
further investigation into the metabolism and clearance of ayahuasca, which contains MAO-
inhibiting beta-carbolines and DMT, could lead to a better understanding of endogenous 
hallucinatory or psychointegrative phenomenon. 
1.3 Ayahuasca 
The term ‘Ayahuasca’ denotes a traditional Amazonian psychotropic tea obtained by 
boiling the stems and bark of the jungle liana Banisteriopsis caapi typically in combination with 
the leaves of Psychotria viridis or Diplopterys cabrerana [2.1-2.6]. The tea, also known as caapi, 
yage, mihi, dapa, natema, pinde, hoasca, daime, or vegetal, has a millennia-old cultural history of 
indigenous religious and medical use where it continues to hold a highly esteemed position in the 




consume Ayahuasca to promote healing, commune with ancestors, and induce modified states of 
consciousness during religious ceremonies and sacred cleansing rituals [2.5, 2.16]. 
In recent history, the firmly established ancestral use of ayahuasca has been adapted into 
sacramental use by three growing syncretic religious groups which have established churches 
across the Americas and Europe. Two of these religious movements, the Santo Daime and União 
do Vegetal (UDV) claim to have over 10,000 members and have received substantial legal 
protections to consume ayahuasca in the United States in ceremonial practices if appropriate 
paper work has been established [2.17]. In addition, an increasing number of foreigners are 
traveling to the Amazon to participate in ayahuasca retreats and traditional healers are organizing 
ayahuasca ceremonies around the world. This increased use has implications for public health 
[2.18].  
An increasing interest exists for potential medical applications of ayahuasca [2.6, 2.15], 
including its antioxidant, antimutagenic and antigenotoxic activity [2.19]. In addition, there are 
suggestions of its putative psychotherapeutic and rehabilitative effects for conditions such as 
alcoholism, violence, suicidal behaviors, and severe depression, as well as other disorders [2.20-
2.25]. Thus, a detailed examination and understanding of the biochemical parameters affected by 
ayahuasca would add to our understanding of this Amazonian medicine. Such an undertaking 
will require scientifically controlled studies conducted as clinical trials. This will require the 
development of analytical methodologies with the capability to characterize ayahuasca extracts, 
as well as conduct pharmacokinetic and metabolic studies of its components 
Previous research has revealed that Banisteriopsis caapi, contains the -carboline 




of the tea: Psychotria viridis or Diplopterys cabrerana, contains N, N-dimethyltryptamine 
(DMT), a psychedelic 5-HT2A/1A/2C agonist [B.11-B.15]. It has been demonstrated that orally 
administered DMT does not produce psychoactive activity by itself [2.14]. Therefore, the 
dominant theory of ayahuasca’s oral activity has been that the -carbolines reversibly inhibit 
monoamine-oxidase A (MAO-A), effectively preventing oxidative deamination of the usually 
orally inactive DMT and thus allowing its absorption and access to the central nervous system 
[1.10]. More detailed information on the issues of ayahuasca composition, metabolism and 
historical background may be found in the respective introduction of the subsequent chapters.  
1.4 Chapter Contents 
Given the interests and capabilities of our laboratory, and recognition that clinical 
research assessing the potential medicinal uses for ayahuasca will require information regarding 
the composition, pharmacokinetics, metabolism, and clearance of ayahuasca’s major components 
led us to the research presented here. Thus, specific methods for the characterization and 
quantitation of the major constituents of ayahuasca and their metabolites in blood and urine have 
been established. In so doing, we hoped to develop methodology that would be useful in the 
study of ayahuasca in clinical and ethnobotanical research as well as in forensic examinations of 
ayahuasca preparations. In an effort to characterize and quantify the active chemical components 
present in ayahuasca we developed a direct injection/liquid chromatography–electrospray 
ionization-tandem mass spectrometry procedure with the capability to simultaneously quantify 
11 compounds potentially found in ayahuasca. The method utilizes a deuterated internal standard 
for quantitation and affords rapid detection of the alkaloids by a simple dilution assay, requiring 
no extraction procedures. Chapter 2 presents this manuscript entitled ”Direct analysis of 




by liquid chromatography–electrospray ionization-tandem mass spectrometry” which was 
published in the Journal of Chromatography A in December 2009 [3.7]. We hypothesized that a 
simple sample dilution protocol could be used to detect and quantitate the components of 
ayahuasca using LC/MS technology, greatly simplifying the process of characterization and 
providing tremendous analytical advantages over previously reported studies and methods. We 
anticipated that this research would confirm much of the existing data concerning ayahuasca, 
detecting the major components present in ayahuasca as tetrahydroharmine and harmine, 
followed by DMT and harmaline. However, the method also had the capability of looking for 
and detecting other potential components such as harmalol, NMT (N-methyltryptamine), harmol, 
and DMT-N-oxide (DMT-NO) as described in Chapter 2. 
Given that clinical research will require standardization of various ayahuasca 
preparations, we used the new method described in Appendix A in research in collaboration with 
Dr. Leanna Standish of Bastyr University (Kenmore, WA) in a study to measure variations in the 
active constituents of ayahuasca collected from teas brewed and used in ceremonies conducted in 
Peru, Brazil, Hawaii and mainland United States. Appendix A presents this manuscript entitled 
”Cross cultural variations in alkaloid content of ayahuasca teas used in spiritual ceremonies” 
which was submitted to the Journal of Ethnopharmacology in September 2011 and remains 
under review. We hypothesized that application of the new methodology would allow a more 
detailed characterization of ayahuasca preparations. Indeed, the research revealed that levels of 
DMT and harmine remain remarkable similar between different batches of ayahuasca brewed in 
Peru, Brazil, or Hawaii. 
Gaining knowledge of the metabolism of the compounds found in ayahuasca represents 




the metabolism and excretion of DMT and the -carbolines in ayahuasca had yet to be studied 
systematically in humans following ayahuasca administration. Because of an increasing interest 
in the potential for modern medical applications of ayahuasca, as well as concerns regarding 
potential for abuse, both toxicological and clinical research will require information regarding 
the metabolism and clearance of its components. For these reasons, following the successful 
development of a method to characterize ayahuasca, we applied our approach to the study of the 
metabolism of ayahuasca by measuring excretory products in human urine following ayahuasca 
administration. The method for urine analysis, as developed for ayahuasca itself, uses sample 
dilution and high performance liquid chromatography (HPLC)–electrospray ionization–selected 
reaction monitoring tandem mass spectrometry, affording a rapid, sensitive and specific 
characterization and quantitation of the major constituents and metabolites of ayahuasca in 
human urine. We demonstrate the validity and application of our analytical protocol to urine 
samples collected in a pilot study by Dr. Jordi Riba’s lab (Sant Pau, Barcelona, Spain) from three 
individuals that were administered ayahuasca in Chapter 3 in our manuscript entitled 
”Methodology for and the determination of the major constituents and metabolites of the 
Amazonian botanical medicine ayahuasca in human urine” which was published in the Journal of 
Biomedical Chromatography in September 2010 [5.18]. Again avoiding the complications of 
having to conduct multiple extracts and analyses which characterized previous literature 
methods, we hypothesized that the direct analysis-sample dilution protocol and LC/MS/MS 
analysis of urine would permit detection and quantitation of known metabolites of the constituent 
compounds and would also permit detection of previously unreported metabolites. We observed 
that tetrahydroharmine appears excreted as the major harmala alkaloid and that the major 




N-oxide: DMT-N‐oxide, a new finding in humans. Very little DMT was detected in urine, despite 
the inhibition of monoamine oxidase afforded by the presence of the harmala alkaloids in 
ayahuasca 
Further toxicological and clinical research on ayahuasca will also require research on the 
pharmacokinetics and clearance of the major constituents of ayahuasca in human blood. Hence 
we modified our method for quantification in urine and created a suitable method for 
quantification in human blood plasma. A combination of two analytical techniques [HPLC with 
ultraviolet and/or fluorescence detection and gas chromatography with nitrogen-phosphorus 
detection], have historically been used for the analysis of some of the constituents of ayahuasca 
in blood following its oral consumption. We report here a single methodology for the direct 
analysis of 14 of the major alkaloid components of ayahuasca, including several known and 
potential metabolites of DMT and the harmala alkaloids in blood plasma. We hypothesized that a 
method using a 96‐well plate/protein precipitation/filtration approach for plasma samples, and 
analysis by HPLC–ion trap–ion trap–mass spectrometry using heated electrospray ionization to 
reduce matrix effects, would permit the rapid, specific and sensitive analysis of the target 
components in plasma following ayahuasca administration. Chapter 4 presents the manuscript 
entitled ”Methodology for determining major constituents of ayahuasca and their metabolites in 
blood” which was published in Journal of Biomedical Chromatography in April 2011 [B.24]. We 
demonstrate for the first time that DMT‐N‐oxide also represents a major circulating product of 
metabolism in the blood following ayahuasca administration. The method also demonstrates 





In further collaboration with Dr. Jordi Riba, we were also able to apply both the urine and 
blood methodology to further and more fully characterize the metabolism and urinary disposition 
of DMT and the harmala alkaloids in a group of healthy volunteers following ayahuasca 
administration. Twenty-four hour urine samples were obtained by Dr. Riba’s lab from 10 healthy 
male volunteers following administration of an oral dose of encapsulated freeze-dried ayahuasca 
(1.0 mg DMT/kg body weight). These urine samples were assayed using our established 
analytical method involving HPLC / electrospray ionization /selected reaction monitoring / 
tandem mass spectrometry. Appendix B presents this manuscript entitled ‘Metabolism and 
disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of 
ayahuasca’ which was published in the Journal of Drug Testing and Analysis in April 2012. We 
observed that harmol, harmalol and tetrahydroharmol conjugates were most abundant in urine 
suggesting that O-demethylation plus conjugation represent an important but probably not the 
only metabolic route for the harmala alkaloids in humans. We found that less than 1% of the 
administered DMT dose was excreted unchanged and that most was recovered as indole-3-acetic 
acid with around 10% being recovered as DMT-N-oxide, suggesting the existence in humans of 
alternative metabolic routes for DMT other than biotransformation by MAO. 
One of the major reasons for undertaking studies of ayahuasca was to gain further insight 
into the metabolism and clearance of DMT in the presence of an MAO inhibitor, such as the 
harmalas. Elucidating the presence and purpose of endogenous N, N-dimethyltryptamines such 
as DMT in humans has been a major focus of our laboratory. The results of our investigation into 
ayahuasca metabolism suggest that N-oxidation represents a major metabolic route for DMT 
clearance in humans, particularly if MAO becomes inhibited, such as occurs with ayahuasca 




NO compared to DMT has been found in rodents [4.47] suggesting that DMT-NO may represent 
a major in vivo metabolite of DMT, thus potentially functioning as a more readily detectable 
marker for endogenous DMT production than DMT itself [4.31, 4.45, 4.47]. The data from our 
studies represent the first reports of DMT-NO as a metabolite of DMT in human urine and blood 
following ayahuasca administration. This finding has implications for the further study of DMT 
in general, particularly its occurrence or absence as a naturally occurring trace amine in humans. 
Appendix C assesses what we know about endogenous psychedelics and asks the 
question “Are DMT and related indole alkaloids truly present in human biochemistry?” Three 
indole alkaloids that possess differing degrees of psychotropic/psychedelic activity have been 
reported as endogenous substances in humans; DMT, 5-hydroxy-DMT (bufotenine) and 5-
methoxy-DMT. We have undertaken a critical review of 69 published studies reporting the 
detection or detection and quantitation of these compounds in human body fluids. Appendix C 
presents this invited review entitled ”A Critical Review of Reports of Endogenous Psychedelic 
N, N-Dimethyltryptamines in Humans: 1955-2010” which was published in the Journal of Drug 
Testing Analysis in February 2012. In reviewing this literature, we addressed the methods 
applied and the criteria used in the determination of the presence of three N, N-
dimethyltryptamines. The review provides a historical perspective of the research conducted 
from 1955 to 2010, summarizing and critiquing the methods and findings for the individual 
compounds in blood, urine and/or cerebrospinal fluid. The review also discusses the 
shortcomings of the existing data in light of more recent findings and how these may be 
overcome. In particular, we frame the question and address the needs for future research in light 




answers to the question “What could be the functional significance of endogenous 
psychedelics?” 
In Chapter 5, the final chapter, a summary of results and general conclusions are 
presented. We briefly discuss four future collaborative ayahuasca characterization studies for 
which data have already been collected. These studies are intended to prepare for future clinical 
trials with ayahuasca. Some potential future studies are presented and suggestions for the future 
directions of endogenous psychedelics research are offered. 
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The term ayahuasca comes from the Quechua culture of South America and may be 
translated into English as “vine of the souls”. Ayahuasca is a decoction or tea prepared from the 
large, woody, jungle vine (liana) Banisteriopsis caapi in combination with other psychoactive 
plants [2.1]. The traditional preparation of ayahuasca involves boiling or soaking the bark and 
stems of B. caapi and the leaves of the Psychotria viridis, a member of the coffee family 
(Rubiaceae) [2.1-2.6].  
B. caapi contains the beta-carboline harmala alkaloids harmine (1), harmaline (2), and 
tetrahydroharmine (2.3, Figure 2.1) as the major active components [2.7] as well as lesser 
amounts of O-demethylated beta-carboline derivatives [harmol (2.4) and harmolol (2.5), Figure 
2.1] [2.3, 2.4, 2.8-2.10]. P. viridis contains the hallucinogen N, N-dimethyltryptamine [DMT 
(2.6); Figure 2.1], as well as lesser amounts of N-methyltryptamine [NMT (2.7)] and 2-methyl-
1,2,3,4-tetrahydro-beta-carboline [2-MTHBC (2.8), Figure 2.1] [2.3, 2.4, 2.8, 2.11]. The 
phytochemical composition and pharmacology of ayahuasca have been extensively described 
[2.6, 2.12-2.14]. Ayahuasca is, however, often brewed with a variety of other plants. With the 
practice of using different plant combinations, which may contain other hallucinogens such as 5-
methoxy- (2.9, Figure 2.1) and/or 5-hydroxy-DMT (2.10, Figure 2.1), the actual composition 
and, thus, the effects of the brew may vary from region to region as well as with the change of 


















Harmine: R1 =  CH3O, 2.1.1 
Harmol:  R1 =  OH, 2.1.4 
 
 
Harmaline: R1 =  CH3O, 2.1.2 




THH: R1 = H; R2 = CH3; R3 = CH3O, 2.1.3 
2-MTHBC: R1 = CH3; R2 = R3 = H, 2.1.8 
 
 
DMT:  R1 =  R3 = CH3; R2 =  Ø; R4 = H;  R5 =  R6 =  H2, 2.1.6 
NMT: R1 = CH3; R2 =  Ø; R3 = H; R4 = H;  R5 =  R6 =  H2, 2.1.7 
DMT-NO:   R1 =  R3 = CH3; R2 =  O
-
; R4 = H;  R5 =  R6 =  H2, 
2.1.11 
5-OH-DMT:    R1 =  R3 = CH3; R2 =  Ø; R4 = OH;  R5 =  R6 =  
H2, 2.1.10 
5-MeO-DMT:   R1 =  R3 = CH3; R2 =  Ø; R4 =  CH3O;  R5 =  R6 =  
H2,  2.1.9 
d4-5-MeO-DMT:  R1 =  R3 = CH3; R2 =  Ø; R4 =  CH3O;  R5 =  




Ayahuasca is also known as caapi, yage, mihi, dapa, natema, pinde, hoasca, daime, or 
vegetal among various South American groups. Ayahuasca holds a highly esteemed and 
millennia-old position in these cultures’ medical and religious pharmacopeia [2.5, 2.16]. Several 
syncretic religious movements use ayahuasca as a sacrament in Brazil. These movements, the 
União do Vegetal (UDV), the Santo Daime, and the Barquiña, claim to have close to 10,000 
members, and branches have  now spread throughout the industrialized West. The UDV and 
Santo Daime sects have recently received substantial legal protections to use ayahuasca in their 
ritual ceremonies in the US [2.17].  
Due to these legal developments and the attendant media publicity in the US, a 
bourgeoning “ayahuasca tourism” trade in South America, an influx of imported ayahuasca into 
the West for illicit use, and home-brewed preparations utilizing both B. caapi and P. viridis (or 
similar plants), ayahuasca use is increasing significantly. Such use has implications for public 
health [2.18]. However, the possible medical benefits of ayahuasca are also of interest [2.6, 
2.15]. For example, the alkaloids in B. caapi have been demonstrated to be antioxidant with 
antimutagenic and antigenotoxic activity [2.19] as well as demonstrating putative 
psychotherapeutic and rehabilitative effects [2.20, 2.21]. Ayahuasca use also appears to produce 
a persistent, long term up-regulation in the number of serotonin reuptake transporters in blood 
platelets, as has been documented in UDV members relative to ayahuasca-naïve age matched 
controls [2.22]. Conditions such as alcoholism with tendencies toward violence, suicidal 
behaviors, and severe depression [2.23-2.25] have all been correlated with decreased numbers of 
serotonin reuptake transporters, suggesting a potential therapeutic biochemical mechanism for 
ayahuasca treatment in these disorders.  
Given the potential medical applications of ayahuasca, along with increasing use and 
potential for abuse in the US, it is important to be able to characterize its constituents, 
determining their presence and concentrations. In addition, clinical research will require 
standardization of various ayahuasca preparations and the generation of information regarding 
storage stability. A rapid, sensitive, and specific method for characterization of ayahuasca 
preparations is therefore desirable.  
The present manuscript describes a rapid, flexible, specific and sensitive method for the 




protocol uses a small sample size, requires no sample extraction as it is based on sample dilution 
followed by direct injection, and is capable of analyzing 11 known or potential components of 
ayahuasca by liquid chromatography-electrospray-tandem mass spectrometry (LC-ESI-MS/MS), 
quantitating them using a deuterated internal standard. 
2.2 Materials and Methods 
2.2.1 Reagents and Chemicals 
HPLC-grade methanol was purchased from Honeywell Burdick and Jackson 
(Morristown, New Jersey, USA). HPLC-grade water, high purity formic acid, and acetonitrile 
were purchased from J. T. Baker (Phillipsburg, NJ, USA). N-methyltryptamine (NMT), DMT, 5-
hydroxy-DMT (5-OH-DMT), 5-methoxy-DMT (5-MeO-DMT), harmine, harmaline 
hydrochloride dihydrate, harmol hydrochloride dihydrate, and harmalol hydrochloride dihydrate 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tetrahydroharmine was purchased 
from THC Pharm (Frankfurt an Main, Germany). DMT-N-oxide (DMT-NO, 2.11, Figure 2.1) 
and 2-MTHBC were prepared as previously described [2.25]. Deuterated (d4) 5-MeO-DMT 
(alpha, alpha, beta, beta-tetradeutero; 2.12, Figure 2.1) was a gift from Dr. David E. Nichols, 
Purdue University Department of Medicinal Chemistry and Molecular Pharmacology, West 
Lafayette, IN, USA. 
2.2.2 Botanical Raw Material and Ayahuasca 
Ayahuasca samples were prepared by Dr. Leanna Standish at Bastyr University Research 
Center, Kenmore, WA, USA. The test material was prepared from herbicide- and pesticide-free 
specimens of Banisteriopsis caapi and Psychotria viridis maintained in cultivation at 2000 ft 
elevation in the South Kona District of Hawaii. These materials were vegetative clones of 
specimens collected in Pucallpa, Peru, in 1982 [2.4].  B. caapi vine and leaves of P. viridis were 
harvested in late January 2009.  The B. caapi vine was collected from a single plant which was in 
light pink bloom. P. viridis leaves were collected from several plants. Samples of the plants were 
sent to the Missouri Botanical Garden where they were authenticated. The three unique samples 
used for the analyses were prepared from fresh P. viridis leaves 8-12 cm in length and freshly cut 




Bastyr University Botanical Medicine Laboratory the fresh plant materials were refrigerated.  At 
the start of decoction plants materials and water were at room temperature. 
Aqueous decoctions of each plant were prepared from freshly harvested material. The 
vine and leaves were washed in distilled water; the vine macerated, then slowly decocted in 11 
liters of double distilled water for 10 hours. Samples derived from two extracts made at the same 
time which varied in the number of P. viridis leaves (300 or 150) while keeping the B. caapi vine 
biomass constant.  At the end of the 10 hour decoction the extracts were bottled, frozen at -70
o
C, 
then shipped on dry ice to Dr. Barker’s laboratory. 
All ayahuasca samples were thawed upon receipt, aliquoted and stored at -80
o
C until 
analyzed. No sample was assayed that had undergone more than two freeze-thaw cycles. 
2.2.3 Preparation of standards and samples for analysis 
Stock standard solutions (1 mg/ml) of the 11 selected compounds and the internal 
standard were prepared individually in methanol in 10 ml amber glass vials with Teflon lined 
screw-cap closures and stored in a freezer at -20
o 
C. Working standards were prepared in 
methanol at selected concentrations by serial dilution. The standard mixes were pipetted into 5 
ml conical tubes. The methanol was removed by gentle evaporation over dry nitrogen and the 
residues were dissolved in amounts of 90% H2O/0.1% formic acid:10% acetonitrile/0.1% formic 
acid mobile-phase solution corresponding to the  sample dilution experiment being conducted. 
Standard curve data points at 6 selected concentrations (including zero) specific to the expected 
concentration range for each compound (determined from preliminary analysis) were prepared to 
determine linearity of response,  to collect data for the quantitation of samples, and to determine 
method performance. 
Ayahuasca samples were well mixed and 100 μl of the sample were transferred to a 5 ml 
conical glass tube. The samples were then diluted, with mixing, to varying concentrations (10X, 
20X, 100X and 200X) using 90% H2O/0.1% formic acid:10% acetonitrile/0.1% formic acid 
mobile phase solutions. 
Methanol (20 μul) containing 1ng/μul internal standard d4-5-MeO-DMT was added 




dilutions of the 11 compound stock standard mixes or Ayahuasca samples (200 ul of diluted 
sample) were filtered through 0.4 um filters (Nalgene, NalgeNunc, Rochester, NY, USA) and 
100 μl of the filtrate were added to individual autosampler vials containing dried internal 
standard. The samples were thoroughly mixed by vortexing. The ayahuasca samples and mixed 
standards were transferred to the HPLC autosampler and 10 μl were injected for analysis. 
2.2.4 LC-ESI-MS/MS analysis 
Analyses were conducted using an Agilent 1200 series LC system (Agilent Technologies, 
Palo Alto, CA, USA) equipped with an Agilent G1367A HiP ALS autosampler, an Agilent 
G1311A Quaternary micropump, and an Agilent G1332A degasser interfaced to a TSQ Quantum 
Access 1.5 SP1 tandem MS (Thermo Fisher Scientific, Waltham, MA, USA) with electrospray 
ionization (ESI) operated in the positive ion mode.  
Chromatographic separation was achieved on a 1.8 μm 4.6 x 50 mm (i.d.) Agilent 
ZORBAX Eclipse Plus C18 rapid resolution HT threaded column with an Alltech Direct-
Connect Column 2 μm pre-filter (Deerfield, IL, USA) using gradient elution. The following 
gradient system was used as the mobile phase; A (0.1% formic acid in H20) and a mobile phase 
B (0.1% formic acid in acetonitrile) delivered at a constant flow rate of 0.3 ml/min; A:B 90:10 (0 
min)- 90:10 (1 min)- 50:50 (5 min)- 50:50 (6 min)- 2:98 (7 min)- 2:98 (9 min) – 90:10 (10 min)- 
90:10 (23 min), allowing for re-equilibration. Samples and standards were analyzed using a 20 μl 
injection volume. 
The MS/MS analysis was performed using selected reaction monitoring (SRM) of the 
protonated molecular ions for the analytes. The m/z transitions and MS parameters for analytes 
and internal standards are given in Table 1. The spray voltage was 4000 V, sheath gas (nitrogen) 
pressure 50 psi, capillary temperature 310
o 
C, and collision pressure was 1.5 psi. Generation of 
detection data and integration of chromatographic peaks were performed by Xcalibur 2.0.7 
Thermo Fisher Scientific (Waltham, MA, USA) LCquan 2.5.6 QF 30115 software.  
Identification of the compounds was based on the presence of the molecular ion at the 
correct retention time, the presence of three transition ions and the correct ratio of these ions to 





The concentration of compounds in ayahuasca samples was determined from the peak 
area ratio of the target analyte to that of the internal standard (d4-5-MeO-DMT; Table 2.2), by 
reference to calibration curves prepared by spiking water with each of the 11 substances and an 
equivalent amount of internal standard. If the concentration of the sample was observed to be 
outside the measured range, the sample was re-analyzed after further dilution with mobile phase 
and the original concentration calculated by extrapolation. Values determined from repeated 
analyses of n aliquots of samples or standards were expressed as their arithmetic mean. The 
percent relative standard deviation (%RSD) was also calculated for standards, as well as the 
method bias (100 times the observed concentration minus target concentration divided by target 
concentration), for each standard curve concentration. Standard deviations were calculated for n 
determinations of samples as noted. Inter- and intra-assay %RSDs were also determined. The 
method limits of detection (LOD; concentration response greater than 3-times baseline noise) 
and limits of quantitation (LOQ: multiplying the LOD by 10 and adding the %RSD) were also 
determined for each compound using fortified water samples.  
2.3 Results 
2.3.1 Validation of the Method 
Each of the compounds gave high yields of molecular ions (M+H)
+
 using the mobile 
phase system and electrospray ionization parameters described (Table 2.1). Product ions were 
also formed with good efficiency. However, for many of the compounds, the third product ion 
was less than 10% of the base peak. Nonetheless, adequate sensitivity was achieved to allow 





Using the LC-MS/MS multi-component method described, the chromatographic and/or 
mass separation of the 11 selected compounds was completed within 23 minutes. The first 
analyte (5-OH-DMT) eluted after 2 min while the last analyte (harmine) eluted at less than 9 
min. The remaining time was used for column cleaning and re-equilibration to assure consistent 
analysis. Data for the retention time of each compound and their consistency, and the analytical 
imprecision for each analyte are presented in Table 2.2. Representative chromatograms for each 
standard analyte are shown in Figure 2.2, and a representative ayahuasca sample is shown in 
Figure 2.3. 
Calibration curves for each compound were linear over the range of concentrations 
examined (5 – 100 ng/mL or 5 – 100 μg/ml, depending on the compound; Table 2.2). The linear 
regression equations and coefficients of correlation are presented in Table 2.2 where y and x 




respective corresponding calibration concentrations. The confidence parameters for the method 
(Bias, %RSD, LOD, LOQ, intra- and inter-assay precision) for determination of the 11 
compounds are presented in Table 2.2. Calculations of method bias and %RSDs suggest that the 
dilution approach and the rather modest sample manipulations do not lead to any significant 
losses of analytes in the process, with recoveries being near quantitative. 
Matrix effects were assessed by analyzing ayahuasca samples at various dilutions (10X, 20X, 
100 X and 200X). When diluted less than 20X, some retention time variability (<1%) and ion 
suppression (<10%) due to apparent matrix effects were noted (data not shown) but were not 
significant. Observed effects were likely due to overloading the capacity of the column with the 
major alkaloid components of the ayahuasca. In support of this interpretation, samples could be 
assayed at 10:1 dilutions without significantly compromising overall analytical performance or 
results. However, such lower dilution analyses had to be conducted with smaller injection 
volumes since the concentrations of some components (THH, for example) overwhelmed the 
column capacity and dramatically affected peak shape. Dilution of the sample up to 200:1 gave 
highly reproducible retention times (Table 2.2), no indication of ion suppression or enhancement 
and did not compromise the ability to achieve detection and/or quantitation of the components of 
ayahuasca. Further dilution could also have been readily applied if necessary. A dilution factor of 
200:1 was subsequently used for all analyses.   
Other sample components did not produce any evident interference in the analysis 
although a few peaks possessing the same (M+H)
+
 ions as the target analytes were evident in the 
chromatograms. Only 5-MeO-DMT and harmol were affected by background but this did not 
compromise either detection or confirmation of the presence or absence of either compound 









Figure 2.2. Representative chromatogram of reference standards illustrating retention times and 
the molecular ion and product ion monitored (200 ng/ml of each; RT= retention time in minutes). 
 
D4-5-MeO-DMT 
223.2 → 178.1 
Harmaline 
215.1 → 171.1 
Harmine 
213.1 → 170.1 
DMT-NO 






189.2 → 144.1 
5-OH-DMT 
205.2 → 160.1 
5-MeO-DMT 
219.2 → 130.1 
Harmol 
199.1 → 171.1 
NMT 
175.2 → 144.1 
Harmalol 




Figure 2.3. Representative chromatogram of an ayahuasca sample (Sample 5 shown at 200:1 
dilution; RT= retention time in minutes). 
Harmalol 
201.1 → 160.1 
5-OH-DMT 
205.2 → 160.1 
NMT 
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5-MeO-DMT 
219.2 → 130.1 
D4-5-MeO-DMT 
223.2 → 178.1 
DMT 






205.2 → 144.1 
Harmine 
213.1 → 170.1 
Harmaline 




2.3.2 Characterization of ayahuasca preparations 
Quantitation of the components of ayahuasca in various preparations (3 unique samples) 
is presented in Table 2.3. DMT-NO, a major metabolite of DMT in mammalian species, was not 
detected in the ayahuasca preparations examined (Table 2.3). Detectable concentrations of 5-
MeO-DMT, 5-OH-DMT, and 2-MTHBC were observed in some samples (data not shown). The 
major components observed were THH and harmine, followed by DMT and harmaline. 
Harmalol, NMT and harmol were also present but in significantly smaller concentrations.  
Several of the samples (3 and 5 as single-blind duplicates, 6 as a concentrate of 3 and 2 as 
a concentrate of 1) were derived from the same batch but underwent further heating and 
concentration. This process seems to have altered the concentration ratios of some of the 
components in a non-linear fashion, suggesting that the process of continued heating/boiling or 
extended storage may lead to analyte decomposition or interconversion. 
Solutions of the target compounds in water were stable for the period of time examined 
(6 months) when stored at -20
o 
C and kept from exposure to light by use of amber vials. 
Similarly, ayahuasca samples were stable for the same period of time when retained under the 
same conditions. However, preliminary data (not shown) indicate that the ayahuasca preparations 
are susceptible to degradation and compound interconversion through prolonged exposure to 
room temperature conditions and these changes are accelerated by exposure to light (data not 
shown) and changes in pH that occur as the preparations age. These and related data will be the 










Table 2.3. Mean concentrations (mg/mL +/- standard deviation) plus or minus standard 
deviations of various alkaloids found in ayahuasca samples quantified using the herein described 





































































































































































 A range of different alkaloids, other than the 11 examined here, have been reported to be 
present in ayahuasca; tetrahydro-beta-carboline (THBC), 6- and 5-methoxy-tryptamine, 2-
methyl-6-methoxy-THBC, 1, 2-dimethyl-6-methoxy-THBC [2.2, 2.6, 2.8, 2.12-2.14], in addition 
to the pyrrolidine alkaloids shihunine and dihydroshihunine [2.27]. These and others are 
apparently minor components and the variation in composition is, in many cases, thought to be 
due to the addition of other plant species to the brews. For this reason 5-MeO-DMT and 5-OH-
DMT have been included in the present assay, as they are also known to be present in some of 
the plants used in ayahuasca preparations and their presence could potentially contribute 
significantly to their effect [2.2, 2.28]. The samples were also examined for the presence of 




ayahuasca preparations. Although a major DMT metabolite in mammals, it appears to be absent 
from the preparations of ayahuasca examined here. 
B. caapi has been reported to contain between 0.05% dry weight to 1.95% dry weight 
harmala alkaloids [2.3, 2.4, 2.8] with a mean of 0.51%, consisting of primarily harmine, 
harmaline, tetrahydroharmine (THH), harmol, and harmalol [11] The results of the present 
analyses are consistent with these observations, and the quantities of the compounds observed 
are very similar to those reported by others [2.28]. 
Preparation of ayahuasca for chemical analysis has often involved liquid-liquid extraction 
of the target alkaloids [2.3, 2.8, 2.29-2.31]. A solid phase extraction method has also been 
described [2.32]. These methods subsequently analyze the extracted components by gas 
chromatography using various detectors, such as flame ionization, nitrogen-phosphorous or mass 
spectrometry [2.3, 2.8, 2.29-2.32]. Unfortunately, many of the manuscripts provide little or no 
data concerning recovery efficiencies for the targeted analytes, and the number of analytes in 
each case is somewhat limited.  
However, because the alkaloids are already extracted in an aqueous decoction, several 
researchers have chosen to use sample dilution and filtration, or centrifugation followed by liquid 
chromatographic analysis [2.3, 2.7, 2.33] using UV or fluorescence detection [2.3, 2.7] or mass 
spectrometry [2.33] (LC/atmospheric pressure chemical ionization APCI/MS). Such direct 
analysis avoids the analytical complications that encompass liquid-liquid extraction protocols, 
such as pH adjustments, solvent evaporation, the relative selectivity of the extraction, and analyte 
recovery. 
The HPLC-fluorescence method developed by Callaway et al. (1996) [2.7] utilized either 
a 10:1 [2.7, 2.28] or 100:1 [2.7] mobile phase dilution protocol. The 10:1 dilution protocol gave 
excellent limits of detection and quantitation. Since the concentrations of the major components 
are quite high in these extracts this is not a concern, and the method has been applied to many 
ayahuasca preparations in the last decade. 
Kawanishi et al. (1998) [2.33] reported using freeze-dried material (1 mg) dispersed into 
40 μl of ethanol (approximately 40:1 dilution) which was subsequently directly injected after 




did not acquire multiple product-ion data (Multiple Reaction Monitoring, MRM).  Instead, it was 
used to conduct targeted (M+H)
+ 
comparisons to reference materials, identifying a number of 
ayahuasca constituents in this manner. 
A sample dilution protocol was chosen for the present study for several reasons. First, by 
utilizing modern mass spectrometric instrumentation and methods, we are able to detect and 
quantitate 11 different alkaloids in our ayahuasca preparations at dilutions up to 200:1.  At the 
same time, we attained better overall sensitivity for detection and limits of quantitation than 
previous methods while eliminating potential matrix effects. Furthermore, the method confirms 
the identity of the analyte by monitoring the (M+H)
+
 ions and obtaining up to three product ions 
whose presence and ratios can be used to assure the absence of interferences that may arise from 
direct injection. Further an examination of ion-mass contribution (cross-talk) for each the 
compounds/masses monitored gave no indication that any of them interfered with the detection, 
confirmation or quantitation of any of the other substances.  
The present method has several distinct advantages over the classical LC with UV or 
fluoresence detection approach. The LC/MS/MS method allows use of a relatively short LC 
gradient program that, while not always obtaining temporal separation of components, allows for 
complete separation by mass. The LC program employed by Kawanishi et al. (1998) [2.33] was 
at least 70 minutes long, precluding its use for routine analysis. A dilution protocol also avoids 
the problems noted above with liquid-liquid extraction, and makes feasible the analysis of a 
range of different polarity components in a single sample. In this regard, the method has the 
flexibility to be expanded to include other compounds of interest by simply adding other 
components to the analysis after a simple determination of mass spectral properties and retention 
time data. In most cases the analyst does not have to consider extraction protocol changes or 
recovery of the new components because no extraction is involved.  
The data also suggest that prolonged heating/boiling of the ayahuasca preparations leads 
to inter-conversion of some of the components. This appears to occur to a significant degree for 
the changes seen in THH, harmine and harmaline levels between samples undergoing further 
heating to attain higher concentrations of the components (See Table 2.3). This phenomenon, an 




reported by Callaway, et al. [2.28] and constitutes another source of potential variability of 
results among ayahuasca preparations.  
Several solutions to the variability in composition of ayahuasca preparations have been 
utilized or proposed by researchers that have conducted human studies. One theoretical approach 
is the use of “pharmahuasca” [2.14], combining pure DMT and harmala alkaloids to produce a 
pharmaceutical-grade ayahuasca. This approach, however, eliminates from consideration the 
possible synergistic role of the trace components of ayahuasca brews. A more popular and 
effective approach has been the use of encapsulated, freeze-dried material obtained from large 
batches of ayahuasca prepared under an exacting protocol [2.15]. Once prepared, this 
standardized  preparation can be assayed, freeze-dried and stored under dry conditions for further 
use. For purposes of human studies, this approach also avoids the placebo-vs-drug problem that 
arises from the taste and odor characteristic of ayahuasca. Another approach has been the use of 
large, well-characterized batches of ayahuasca which are then frozen at -80
o 
C and thawed for 
use. Masking the taste remains a problem, however. In either of these cases, analytic 
methodology for the full characterization of the materials is required. 
The assay described here is ideal for such purposes given the demonstrated ability to 
provide rapid, flexible, accurate and precise analysis over the range of concentrations examined.  
The use of d4-5-MeO-DMT as an internal standard appears to be quite adequate in terms of 
linearity and quantitation of the range of alkaloid concentrations determined.  
The present method may also provide an analytical approach to study metabolism of 
ayahuasca in blood and urine. Indeed, preliminary data obtained from urine samples collected 
from individuals who have consumed ayahuasca suggest that this methodology may be directly 
applied to diluted and filtered urine samples before or after enzyme treatment of the samples to 
release conjugates (data not shown). Similar results have also been obtained using a protein 
precipitation/dilution approach for blood samples (data not shown).  
2.5 Conclusions 
A direct injection/liquid chromatography-electrospray ionization- tandem mass 
spectrometry procedure has been developed for the simultaneous quantitation of 11 compounds 




utilizes a deuterated internal standard, d4-5-MeO-DMT, for quantitation. This method affords 
rapid detection of alkaloids by a simple dilution assay requiring no extraction procedures. In 
addition, the method affords an extremely high degree of specificity for the compounds in 
question, as well as low limits of detection and quantitation. Its application to 3 different 
ayahuasca preparations has been demonstrated. This method should find application in the study 
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The term ‘ayahuasca’ denotes a decoction or tea traditionally prepared by South 
American tribes by boiling or soaking the bark or the stems of the large, woody, jungle vine 
(liana) Banisteriopsis caapi and the leaves of Psychotria viridis, a member of the coffee family 
(Rubiaceae) [3.1-3.6]. The resulting tea is consumed in varying amounts, depending on the 
potency of the preparation, so as to attain different states of altered consciousness. Because of 
this and related effects, ayahuasca continues to hold a highly esteemed and millennia-old 
position in the culture of various South American groups as part of their medical and religious 
pharmacopeia. 
There is now an increasing interest in modern medical applications of ayahuasca, as well 
as growing concern regarding its potential for abuse. Indeed, several syncretic religious 
movements originating in South America that use ayahuasca as a sacrament have spread 
throughout the industrialized West. A bourgeoning “ayahuasca tourism” trade in South America, 
an influx of ayahuasca into the West for illicit use, and the consumption of home-brewed 
preparations utilizing both B. caapi and P. viridis (or similar plants), are seen as having 
implications for public health [3.7] and for various national and/or international regulatory 
agencies. The possible medical benefits of ayahuasca [3.6, 3.8] include its antioxidant, 
antimutagenic and antigenotoxic activity [3.9] as well as putative psychotherapeutic and 
rehabilitative effects [3.10, 3.11] and a potential to treat conditions such as alcoholism with 
tendencies toward violence, suicidal behaviors, and severe depression [3.12-3.15]. Thus, an 
examination of the biochemical parameters of ayahuasca, including its metabolism and 




The psychotropic effects of ayahuasca are produced by the combination of components 
extracted by the boiling process described above. B. caapi contains the beta-carboline harmala 
alkaloids harmine (3.1.1), harmaline (3.1.2), and tetrahydroharmine [THH (3.1.3)] as the major 
active components as well as lesser amounts of the O-demethylated beta-carboline derivatives 
harmol (3.1.4) and harmalol (3.1.5) (Figure 3.1) [3.3, 3.4, 3.16-3.19]. P. viridis contains the 
psychedelic compound N, N-dimethyltryptamine [DMT (3.1.6); Figure 3.1)], as well as lesser 
amounts of N-methyltryptamine [NMT (3.7)] and 2-methyl-1,2,3,4-tetrahydro-beta-carboline [2-
MTHBC (3.1.8), Figure 3.1] [3.5, 3.6, 3.16, 3.20]. Extensive information regarding the 
phytochemical composition and general pharmacology of traditional ayahuasca has appeared in 
previous publications [3.6, 3.19-3.23]. Similarly, blood pharmacokinetic data for many of the 
major constituents of ayahuasca and, subsequently, methods for their analysis in blood either 
individually or in combination, have been described [3.19, 3.22, 3.24-3.27]. However, no 
literature exists concerning urinary excretion, clearance and metabolism of the known major 
constituents of ayahuasca in combination. Only two reports of the analysis of a select few of 
ayahuasca’s known components in urine have been published [3.28, 3.29] and no data 
concerning the fate of ayahuasca derived DMT. 
The present manuscript describes the development of a rapid, specific, and sensitive 
method for the direct qualitative and quantitative analyses of 12 known or potential major 
alkaloid components and metabolites found in human urine following oral administration of 
ayahuasca. Such a method is needed in order to understand the metabolism and clearance of 
ayahuasca’s major constituents, particularly for conducting toxicological, clinical or other basic 
science research. To demonstrate the utility of the procedures described, the method has been 




ayahuasca of a known composition by an oral route [3.8, 3.20, 3.22, 3.30]. The results of the 
analyses of these urine samples before and after treatment with sulfatase/glucuronidase are also 
reported.  
3.2 Experimental 
3.2.1 Solvents and Standards 
HPLC-grade methanol was purchased from Honeywell Burdick and Jackson 
(Morristown, New Jersey, USA). HPLC-grade water, high purity formic acid, and acetonitrile 
were purchased from J. T. Baker (Phillipsburg, NJ, USA). N-methyltryptamine (NMT), DMT, 5-
hydroxy-DMT (5-OH-DMT), 5-methoxy-DMT (5-MeO-DMT), harmine, harmaline 
hydrochloride dihydrate, harmol hydrochloride dihydrate, and harmalol hydrochloride dihydrate 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tetrahydroharmine was purchased 
from THC Pharm (Frankfurt am Main, Germany). DMT-NO (3.1.11, Figure 3.1) and 2-MTHBC 
were prepared as previously described [3.31]. N,N-Dimethylkynuramine (DMK, 3.1.13, Figure 
3.1) was a gift from Dr. Laurent Micouin, Laboratoire de Chimie Thérapeutique, Faculté des 
Sciences Pharmaceutiques et Biologiques, Paris, France. Deuterated (d4) 5-MeO-DMT (alpha, 
alpha, beta, beta-tetradeutero; 3.1.12, Figure 3.1) was a gift from Dr. David E. Nichols, Purdue 







 Figure 3.1. Structures of the compounds examined in urine samples. 
 
 
       
 
         
         
 
Harmine: R1 =  CH3O, 3.1.1 
Harmol:  R1 =  OH, 3.1.4 
 
 
Harmaline: R1 =  CH3O, 3.1.2 






THH: R1 = H; R2 = CH3; R3 = CH3O, 3.1.3 
2-MTHBC: R1 = CH3; R2 = R3 = H, 3.1.8 
 
 
DMT:  R1 =  R3 = CH3; R2 =  Ø; R4 = H;  R5 =  R6 =  H2, 3.1.6 
NMT: R1 = CH3; R2 =  Ø; R3 = H; R4 = H;  R5 =  R6 =  H2, 3.1.7 
DMT-NO:   R1 =  R3 = CH3; R2 =  O
+; R4 = H;  R5 =  R6 =  H2, 3.1.11 
5-OH-DMT:    R1 =  R3 = CH3; R2 =  Ø; R4 = OH;  R5 =  R6 =  H2, 3.1.10 
5-MeO-DMT:   R1 =  R3 = CH3; R2 =  Ø; R4 =  CH3O;  R5 =  R6 =  H2,  3.1.9 












Stock standard solutions (1 mg/ml) of the 12 selected compounds and the internal 
standard were prepared individually in methanol in 10 ml amber glass vials with Teflon-lined 
screw-cap closures and stored in a freezer at -20
o 
C. Working standards were prepared in 
methanol at selected concentrations by serial dilution and pipetted into 5 ml conical tubes. The 
methanol was removed by gentle evaporation over dry nitrogen and the residues were dissolved 
in amounts of 90% H2O/0.1% formic acid: 10% acetonitrile/0.1% formic acid mobile-phase 
solution corresponding to the appropriate sample dilution experiment being conducted.  
3.2.2 Preparation of Urine Samples  
Urine samples were well-mixed and 100 µl of the sample were transferred to a 5 ml 
conical glass tube. The samples were then diluted to the appropriate volume using 90% 
H2O/0.1% formic acid:10% acetonitrile/0.1% formic acid mobile phase solution. Dilutions of 
standards in blank urine (pooled, 0 time point/pre-ayahuasca-administration collections) of 5:1, 
10:1 and 20:1 were examined. Standard curve data points at 7 or 8 selected concentrations 
(including zero) specific to the expected concentration range for each compound (determined 
from preliminary analyses) were prepared in blank urine and used to examine linearity of 
response, to collect data for the quantification of samples, and to determine method performance. 
Spiked water samples were similarly prepared and used to examine matrix effects and relative 
analyte recovery. 
Methanol (20 µl) containing 1ng/µl internal standard d4-5-MeO-DMT was added directly 
into individual autosampler vials and dried completely under nitrogen. Various serial dilutions of 
the 12 compound stock standard mixes or urine samples (1 ml) were filtered through 0.4 um 




individual autosampler vials containing dried internal standard. The urine samples were 
thoroughly mixed by vortexing. The urine samples and mixed standards, spiked into urine or 
water, were transferred to the HPLC autosampler and 10 µl were injected for analysis. 
3.2.3 Freeze Dried Ayahuasca Administration and Urine Collection  
Ayahuasca was administered orally as an encapsulated lyophilizate obtained from a large, 
10 L batch which was freeze-dried, homogenized and analyzed for alkaloid contents by HPLC 
[3.19]. One gram of this freeze-dried material contained 4.77 mg DMT, 10.45 mg harmine, 0.68 
mg harmaline, and 9.04 mg THH. Based on previous ayahuasca dosing studies [3.8, 3.20, 3.22, 
3.30], a dose of 0.75 mg DMT/kg body weight was chosen. Freeze-dried ayahuasca was 
administered in 00 size gelatin capsules containing 0.5, 0.25, or 0.125 g. Each volunteer received 
their calculated individual dose by consuming the correct combination of these capsules. 
Urine samples were obtained following dosing to 3 healthy male volunteers with previous 
experience in psychedelic drug use. The study was approved by the local ethics committee 
(Hospital de Sant Pau, Barcelona) and the Spanish Ministry of Health. Signed informed consent 
was obtained from all participants. Urine was collected for the following time intervals relative 
to ayahuasca administration: 0 (predose), 0-4h, 4-8h and 8-24h. The collected urine volume 
across each time interval was noted, the pooled urine was well mixed and 50 ml aliquots were 
separated and stored at -80 ºC until analysis. Samples were shipped and received on dry ice and 
underwent a single freeze-thaw cycle prior to analysis. 
3.2.4 Enzyme Hydrolysis  
Enzyme hydrolysis of the urine samples was performed by preparing 1.0 M sodium 




water and 33 ml of glacial acetic acid. Glucuronidase/sulfatase buffer was prepared by dissolving 
1 bottle (2 million units) of Bβ-glucuronidase/sulfatase from limpets (Patella vulgata) Type L-II  
(Sigma-Aldrich, St. Louis, MO, USA) in 400 ml of distilled water. Acetate buffer (1200 ml) was 
then mixed with 400 ml glucuronidase/sulfatase buffer. Glucuronidase/sulfatase /acetate buffer 
mix (300 µl) was then added to each tube containing 500 µl of individual urine samples and 
incubated for 1 hour in a 65
o 
C shaking water bath, and then allowed to cool to room 
temperature. Samples were then treated as described above, accounting for the dilution involved 
in the hydrolysis process. 
3.2.5 Determination of Matrix Effects  
Matrix effects were examined using three blank urine samples (0-time samples from the 
three individuals’ samples examined here, prior to ayahuasca administration) and water (n = 3). 
The urines and water were treated as described above (only a 10:1 dilution was examined) and 
then fortified at five different concentrations of each of the standards (0, 10, 25, 50 and 100 
ng/ml). The data were examined to determine the slope of the curves so generated and the slopes 
were compared, determining the percent relative standard deviation (%RSD) for each compound. 
3.2.6 LC-ESI-MS/MS analysis  
The LC/MS/MS analyses were conducted as previously described [3.23] using a 
validated method for the analysis of 12 of these alkaloids in ayahuasca preparations themselves, 
with modifications, and with the addition of the compound DMK (3.13, Figure 3.1) to the 
analysis. Thus, analyses were conducted using an Agilent 1200 series LC system (Agilent 
Technologies, Palo Alto, CA, USA) equipped with an Agilent G1367A HiP ALS autosampler, 




G131gA TCC column oven operating at 25
o 
C was interfaced to a TSQ Quantum Access 1.5 SP1 
tandem MS (Thermo Fisher Scientific, Waltham, MA, USA) with electrospray ionization (ESI) 
operated in the positive ion mode.  
Chromatographic separation was achieved on a 1.8 μm 4.6 x 50 mm (i.d.) Agilent 
ZORBAX Eclipse Plus C18 rapid resolution HT threaded column with an Alltech Direct-
Connect Column 2 μm pre-filter (Deerfield, IL, USA) using gradient elution. The following 
gradient system was used as the mobile phase: A (0.1% formic acid in H2O) and a mobile phase 
B (0.1% formic acid in acetonitrile) delivered at a constant flow rate of 0.3 ml/min throughout 
the analysis; A:B 90:10 (0 min)- 90:10 (1 min)- 50:50 (5 min)- 50:50 (6 min)- 2:98 (7 min)- 2:98 
(9 min) – 90:10 (10 min)- 90:10 (23 min), allowing for re-equilibration. The MS/MS analysis 
was performed using selected reaction monitoring (SRM) of the protonated molecular ions for 
the analytes. The spray voltage was 4000 V, sheath gas (nitrogen) pressure 50 psi, capillary 
temperature 310
o 
C, and collision pressure was 1.5 psi. of high purity argon. Generation of 
detection data and integration of chromatographic peaks were performed by Xcalibur 2.0.7 
Thermo Fisher Scientific (Waltham, MA, USA) LCquan 2.5.6 QF 30115 software.  
Identification of the compounds was based on the presence of the molecular ion at the 
correct retention time, the presence of three transition ions and the correct ratio of these ions to 
one another (+/- 25% relative). 
3.2.7 Determination of Inter- and Intra-assay Variation  
A set of three standard curves prepared in blank urine were assayed on the same day and 




analyzed on three separate days to provide data for inter-assay variability. The %RSD for 
concentrations ranging from 5-200 ng/ml was calculated for each experiment. 
3.2.8 Calculations  
The concentration of compounds in urine samples was determined from the peak area 
ratio of the target analyte to that of the internal standard (d4-5-MeO-DMT; 3.1.12, Figure 3.1), by 
reference to calibration curves prepared by spiking blank urine with each of the 12 substances 
and a consistent amount of IS (internal standard). The transition ions used for quantitation are 
shown in Figure 3.2. If the concentration observed was outside the measured range, the sample 
was re-analyzed after further dilution with mobile phase and the original concentration calculated 
by extrapolation. Values determined from repeated analyses of n aliquots of samples or standards 
were expressed as their arithmetic mean. For the standards the percent relative standard deviation 
(%RSD) was calculated, as was the method bias, as a function of concentration. Standard 
deviations were calculated for n determinations of samples as noted. Inter- and intra-assay 
%RSDs were also determined. Limits of detection (LOD; concentration response greater than 5X 
baseline noise) and limits of quantification (LOQ: the lowest injected concentration having a 
%RSD of less than 15%) were also determined for each compound. To examine matrix effects, 
slopes were calculated for standard curves generated from fortifying 3 different urine samples 
and 3 water samples. The slope and mean of the slopes and of individual urine samples were 
compared to each other and that obtained from the mean of spiked water curves and the %RSD 






3.3 Results and Discussion 
3.3.1 Evaluation of the Method  
Several methods have been reported for the analysis of the major components of 
ayahuasca itself [3.20, 3.23, 3.25, 3.27, 3.32-3.35] and for the analysis of multiple components in 
blood [3.19, 3.22 3.25, 3.26]. However, no comprehensive method measuring major components 
and known or potential metabolites, as reported here, has ever been developed or applied to urine 
samples obtained following ayahuasca administration to humans. This report provides such data 
for the first time, and would be applicable to future toxicological or clinical research of this 
Amazonian medicine. The method described provides a simple, flexible, sensitive and selective 
protocol, as reflected in the performance parameters measured (Table 3.1) and in the 
chromatograms shown.  This approach to conducting the analysis of the components of 
ayahuasca has previously been applied to ayahuasca itself [3.23] using a 200:1 dilution of the 
“tea”. Such direct analysis following dilution has several advantages, permitting analysis of a 
range of compounds in a single injection that would otherwise have to be isolated and analyzed 
by one or more extraction/detection schemes. 
Each of the compounds assayed, including DMK, gave high yields of molecular ions 
(M+H)
+
 using the mobile phase system and electrospray ionization parameters previously 
described [3.23]. The LC/ESI/MS/MS characteristics of DMK have not previously been 
reported, however. DMK gave an excellent yield of the molecular ion (M+H
+
, 193.1) and 
product ions were also formed with good efficiency (58.3, 42.4 and 130.1 at voltages of 13, 63 




was less than 10% of the base peak, adequate sensitivity was achieved to allow inclusion of all 
ions in the identification criteria.  
Using the LC method described, all of the compounds examined were not separated 
temporally. However, all of the compounds were completely separated by mass. A thorough 
examination of ion contribution (cross-talk) between each of the compounds and the masses 
monitored indicated no discernible interference, even at the highest concentrations. The LC 
method employed yielded good peak shape for each analyte, despite the rather diverse chemical 
characteristics of the compounds examined, and appears to also assist in removing possible 
matrix interferences. No substances having the same masses as the target analytes were 
observed, in either the method blanks or zero-time urine samples collected from subjects, which 
would potentially interfere with the detection of the compounds of interest. Similarly, enzyme 
treatment did not produce any compounds that interfered with the analysis. These results suggest 
that the method has a high degree of specificity. A representative chromatogram for analyte 
standards spiked into urine is shown in Figure 3.2, and a representative chromatogram for a 
blank urine sample containing only the internal standard is shown in Figure 3.3.  
Of the three dilutions examined, 5:1, 10: 1 and 20:1, the 10:1 dilution protocol was 
chosen. At 5:1 some issues with peak shape (peak broadening and tailing due to overloading) 
were noted which were eliminated by dilution at 10:1. Dilutions at 20:1 were also quite 
acceptable but the results were, of course, not as sensitive as the 10:1 dilution. Thus, a 10:1 
dilution was subsequently used for all analyses.  
Data for the retention time of each compound and their reproducibility, as well as the 




curves for each compound were linear over the range of concentrations examined (5-200 ng/ml 
Table 3.1) and the linear regression equations and coefficients of correlation for each are 
presented in Table 3.1. The performance parameters for the method (%bias, %RSD, LOD, LOQ, 
intra- and inter-assay precision) for determination of the 12 compounds are also presented in 
Table 3.1. Calculations of method bias and %RSDs show that using a 10:1 dilution and 
performing minimal sample manipulations does not lead to any significant loss of analytes in the 
process, with recoveries being near quantitative (compared to responses of equal concentrations 
spiked into water). The limits of detection were in the sub-nanogram range for most of the 
analytes and were more than adequate for the detection and determination of concentrations of 
the compounds excreted into the urine following ayahuasca administration. The highly linear 
response of the analytes over the range of concentrations examined demonstrates the validity of 
the use of the single deuterated internal standard for all 12 compounds. The modest inter- and 
intra-assay variations observed reflect a reliable and reproducible method for detection of the 









Table 3.1. Method performance parameters. LOD = limit of detection (ng/ml); LOQ = 
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Table 3.2. Comparison of line slopes over the range of concentrations examined showing relative 
 (urine versus urine) and general [urine versus mobile phase (MP)] matrix effects (%RSD). 
 







Figure 3.2. Representative chromatogram of reference standards spiked into blank urine (200 
ng/ml of each; RT= retention time in minutes). 
DMT 






205.2 → 144.1 
Harmine 
213.1 → 170.1 
Harmaline 
215.1 → 171.1 
Harmalol 
201.1 → 160.1 
5-OH-DMT 
205.2 → 160.1 
NMT 
175.2 → 144.1 
Harmol 
199.1 → 171.1 
5-MeO-DMT 
219.2 → 130.1 
D4-5-MeO-DMT 
223.2 → 178.1 
DMK 





Figure 3.3. Representative chromatogram of a blank urine sample (4RH3) obtained pre- 
ayahuasca administration (shown at 10:1 dilution; RT= retention time in minutes). 
DMT 






205.2 → 144.1 
Harmine 
213.1 → 170.1 
Harmaline 





205.2 → 160.1 
NMT 
175.2 → 144.1 
Harmol 199.1 → 171.1 
5-MeO-DMT 
219.2 → 130.1 
D4-5-MeO-DMT 
223.2 → 178.1 
DMK 




3.3.2 Matrix Effects 
One concern involving the use of a direct-injection/sample dilution protocol, especially 
with one based on LC/ESI/MS/MS analysis, is matrix effects [3.36-3.40]. Thus, following the 
examples of Matuszewski [3.36, 3.37], we examined both relative and general or absolute matrix 
effects for the twelve compounds examined by comparing the slopes of the standard curves 
generated from spiking standards into water (no matrix) over a range of concentrations versus 
standards similarly spiked into blank urine (n = 3 for each) and by comparing the urines to each 
other (Table 3.2). Ion suppression or ion enhancement would be expected to cause significant 
deviation of the slope of the corresponding compound linear regression curve and would be 
reflected in the %RSD calculated for the mean of n curves. In the present study, no significant 
deviation (>/= 15%) of the slope for any of the compounds was observed (Table 3.2), either 
between urine samples or for urine versus water, illustrating that relative and absolute matrix 
effects were generally not of concern [3.38]. Matrix effects are further mitigated in this method 
by the use of the matrix itself to generate standard curves. DMK was affected to the greatest 
degree of all the compounds examined. While of interest, this observation should not be an issue 
since it was determined from the present study that DMK does not appear as a urinary metabolite 
of DMT following ayahuasca administration and need not be included in future studies.   
3.3.3 Major Constituents and Metabolites of Ayahuasca in Urine  
The application of this method to actual samples has also been demonstrated and the 
results obtained offer new data concerning the metabolism and clearance of the major harmala 
alkaloids of ayahuasca and of DMT, in particular. Because of the limited number of subjects, 




appropriate. A larger study will need to be conducted that includes more subjects and correlation 
of the data with urine creatinine as well as other values. 
The overall chromatography and the detection of the selected alkaloids and metabolites 
present in pre- and post-enzyme treated urine samples collected after ayahuasca administration, 
are presented in Figures 4 and 5, respectively. Tabulation of the concentrations of these 
compounds pre- and post-enzyme treatment of urine as a function of collection interval are 
shown in Table 3.3. As shown in Table 3.3, prior to enzyme treatment of urine, the overall major 
metabolite observed was DMT-NO, peaking at 4-8 hour after ayahuasca administration with 
concentrations of approximately 11 µg/ml (n = 3 individuals). THH was the major component in 
the 8-24 hours samples, with concentrations greater than 5 µg/ml. Free harmalol and harmol 
were also observed in significant µg/ml concentrations. Much smaller amounts of unchanged 
DMT, harmaline and harmine and of 5-OH-DMT, and 2-MTHBC were also detected.  
In urine samples which underwent enzyme hydrolysis with glucuronidase/sulfatase, a 40-
60 fold increase (Table 3.3) in the amount of harmol in the urine samples was observed, making 
harmol (or harmol-glucuronide/sulfate) the most abundant product exctreted. Harmalol 
concentration was increased by a factor of at least 4-fold. Little discernible change in 
concentration was observed for excreted THH, harmine, harmaline, or DMT as a consequence of 
enzyme hydrolysis. DMT-NO concentrations were observed to decrease with enzyme treatment 
of urine but this may be caused by direct chemical effects on the compound produced by heating 
and hydrolysis [3.31]. Enzyme treatment of urine resulted in release of NMT, which was not 
detected in unhydrolyzed samples, and of 2-MTHBC. The presence of 5-OH-DMT was also 
noted in unhydrolyzed urine samples and its concentration was increased following enzyme 





Figure 3.4. Representative chromatogram from a urine sample (4RH12) obtained in the 8-24h 
interval after ayahuasca administration. 
DMT 
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Figure 3.5. Representative chromatogram from an enzyme treated urine sample (4RH12) 
obtained in the 8-24h interval after ayahuasca administration.  
DMT 
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Table 3.3: Concentration of compounds (µg/ml) in urine as a function of collection interval 
(hours) and enzyme (glucuronidase/sulfatase) treatment. 
Concentration of Compounds in Urine
DMT DMT-NO THH HARMINE HARMALINE HARMALOL HARMOL 2MTHBC 5-OH-DMT
0 0 0 0.01 0 0.02 0 0.04 0 0
Collection Interval 0 to 4 0.45 8.66 6.03 0.16 0.51 3.61 2.3 0.02 0.14
(hours) 4 to 8 0.6 11.06 6.27 0.12 0.5 4.04 3.09 0.13 0.16
8 to 24 0.03 1.27 5.4 0.01 0.32 1.25 0.77 0.01 0
Concentration of Compounds in Urine Following Enzyme Treatment
DMT DMT-NO THH HARMINE HARMALINE HARMALOL HARMOL 2MTHBC 5-OH-DMT
0 0 0 0 0 0 0 0.17 0 0
Collection Interval 0 to 4 0.5 8.74 7.25 0.21 0.53 14.16 126.18 0.12 0.2
(hours) 4 to 8 0.48 8.67 6.3 0.18 0.36 11.06 115.49 0.11 0.2
8 to 24 0.02 1.02 4.85 0.06 0.25 5.32 38.93 0 0.02  
 
 The metabolism of  the two major harmala alkaloids in ayahuasca, harmine and 
harmaline, have previously been examined as individual compounds, in separate studies, to 
undergo metabolism by O-demethylation to harmol and harmalol, respectively, followed by 
glucuronidation and/or sulfation [3.41-3.44]. The data from the present study are in agreement 
with these previous findings. The amounts of harmol and harmalol present in the ayahuasca 
consumed in the present study would be expected to provide a minor contribution to the total 
observed in urine, being in the 10’s of µg/ml range versus the 100’s of µg/ml to mg/ml range for 
harmine and harmaline [3.8, 3.20, 3.22, 3.23, 3.30]. Thus, there appears to be significant 
metabolism of these latter compounds.   
In the current study, higher levels of THH were initially detected compared to harmine 
and harmaline in urine (Table 3.3). However, following enzyme hydrolysis of the urine samples, 




It is of interest that the hallucinogenic component of ayahuasca, DMT, when consumed 
alone by the oral route elicits no discernible psychoactivity, due to rapid oxidative deamination 
and peripheral degradation to indoleacetic acid (IAA) mediated by the enzyme monoamine 
oxidase A (MAO-A) [3.20, 3.24, 3.25 3.31, 3.45-3.50]. However, the beta-carboline alkaloids, 
such as harmine and harmaline and, to a lesser extent the THH also found in ayahuasca, are 
reversible inhibitors of MAO-A [3.3, 3.50]. Thus, co-administration of MAO inhibitors (MAOI) 
such as harmine or harmaline allows DMT to become orally active [3.3, 3.46] and would be 
expected to also affect its overall metabolism and excretion profile.  
Several studies have examined the pharmacokinetics of parenterally-administered DMT 
and it is well established that intramuscular (i.m.) or intravenous DMT administered without 
MAO inhibition is rapidly cleared from blood, [3.51, 3.52]  with less than 0.1% of the parent 
DMT being recoverable in human urine within a 24-hour collection period [3.51, 3.53]. In vivo 
animal studies have also demonstrated a very rapid clearance of DMT from various tissues such 
as plasma, brain, and liver [3.47, 3.48, 3.54, 3.55]. 
While oxidative deamination appears to be a major metabolic route, N-oxidation has also 
been identified as an important metabolic pathway of DMT both in vitro [3.31, 3.51, 3.56]  and 
in vivo in rodents and rabbits [3.24, 3.47-3.49]. It is of interest to note that DMT-NO does not 
appear to be a substrate for MAO [3.49, 3.56]. NMT has also been identified as a minor 
metabolite of DMT [3.24, 3.31, 3.51, 3.57] as has 2-methyl-THBC (2-MTHBC) and traces of 
tryptamine and 1,2,3,4-tetrahydro-ß-carboline (THBC) [3.31]. NMT is also a substrate for MAO 
and is subject to be metabolized to IAA. The finding of NMT in the present study suggests that 
formation of NMT from DMT in ayahuasca may also be a minor pathway in vivo and that it may 




detected arises from the ayahuasca itself and not necessarily from DMT metabolism. 
Nonetheless, the latter possibility cannot be excluded. 
It has been demonstrated that iproniazid pretreatment (MAO-A inhibition) increases the 
levels of DMT in vivo in rat brain, liver, kidney, blood, as well as DMT-NO in rat liver [3.48], 
and to increase the urinary excretion of DMT, DMT-NO and NMT in rodents [3.47]. These data 
suggest that MAO inhibition may shift metabolism to these other routes as part of a possible 
compensatory metabolic mechanism. Given the MAO-inhibition effects of ayahuasca, similar 
effects on DMT metabolism would be expected and may explain some of the results. 
The present results suggest that N-oxidation represents a major metabolic route for DMT 
clearance in humans, particularly if MAO becomes inhibited, such as occurs with ayahuasca 
administration, in agreement with the work of Sitaram et al. [3.24]. Sitaram et al.  found an 
approximately 10 times higher concentration of DMT-NO compared to DMT following 
iproniazid pretreatment in rodents [3.47] and noted a 6 times higher concentration of DMT-NO 
compared to DMT in control animals when no MAOI was administered. This suggests that 
DMT-NO may represent a major in vivo metabolite of DMT and may, thus, serve as a better 
marker for endogenous DMT production and metabolism in mammals as well [3.31, 3.45, 
3.47].The data from the present study represent the first report of DMT-NO as a metabolite of 
DMT in the urine of humans following ayahuasca administration or, for that matter, DMT alone. 
This finding has implications for the further study of DMT in general, particularly its occurrence 
as a naturally occurring trace amine in man. The necessity for such studies has gained greater 
impetus with the recent report that DMT may be the endogenous ligand for the sigma-1 receptor 




The origins of the 5-OH-DMT observed are somewhat obscure. It is possible that the 
ayahuasca used in this study contained small quantities of either 5-OH or 5-MeO-DMT, which 
were not originally detected. However, 5-OH-DMT may also be endogenous and may, with 
MAO inhibition afforded by ayahuasca consumption, reach high enough concentrations to 
become more detectable in urine. Further analyses will be required to answer this question. 
DMK has also been reported to be a metabolite of DMT [3.60]. However, this compound 
has only been reported in vitro in whole blood following spiking with DMT. No study has yet to 
examine or determine the presence of this compound as an in vivo metabolite of DMT in any 
species. The present study suggests that, if formed in blood or in the tissues of humans, it is not 
consistently excreted as DMK in the urine, even with MAO inhibition, and after treatment with 
sulfatase/glucuronidase no free DMK is released. However, it remains possible that this 
compound undergoes metabolism to another, as yet undetermined, compound prior to excretion. 
The data also suggest that future studies with clinical administration of ayahuasca would 
benefit from urine collection beyond 24 hours after administration in order to monitor the 
complete disappearance of DMT-NO, THH, harmine, and harmol. 
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Ayahuasca, also known as hoasca, yage, daime, or vegetal in the pharmacopeia of various 
South American groups, is a psychotropic plant tea that has a long cultural history of indigenous 
medical and religious use. The major components of ayahuasca are the hallucinogen N,N-
dimethyltryptamine (DMT) and members of the harmala alkaloid family [4.1-4.6].  
There is an increasing interest in potential medical applications of ayahuasca [4.7-4.8], 
including its antioxidant, antimutagenic and antigenotoxic activity [4.9].  In addition, there are 
suggestions of its putative psychotherapeutic and rehabilitative effects for conditions such as 
alcoholism, violence, suicidal behaviors, and severe depression, as well as other disorders [4.10-
4.17]. Thus, a detailed examination and understanding of the biochemical parameters affected by 
ayahuasca is needed and will no doubt add to our understanding of this Amazonian medicine. 
Clinical research assessing the potential medicinal uses for ayahuasca will require information 
regarding the pharmacokinetics, metabolism, and clearance of ayahuasca’s major components. 
Thus, specific methods for the characterization and quantitation of the major constituents of 
ayahuasca and their metabolites in blood and urine are needed. In this regard, the authors have 
recently reported such a method for urine [4.18]. The present research provides a protocol for 
conducting such analyses in blood.  
Historically, a combination of two analytical techniques, one based on high performance 
liquid chromatography (HPLC) with ultraviolet (UV) and/or fluorescence detection [4.19-4.20] 
and another, using gas chromatography with nitrogen-phosphorus detection (GC-NPD) [4.19-
3.20], have been used for the blood analysis of many of the constituents of ayahuasca following 
oral administration. The major components analyzed in these studies were N,N-




Table 4.1), harmaline (4.1.3), and tetrahydroharmine (THH, 4.1.5; HPLC-UV or fluoresence) 
[4.19-4.20], as well as harmol (4.1.2) and harmalol (4.1.4; HPLC-fluoresence; [4.20]). These 
methods have been applied to blood samples to examine the pharmacokinetics of these 
compounds [4.11, 4.19-4.21].  Such analyses have also been used to correlate blood levels of the 
major components with ayahuasca’s effects on subjective and cardiovascular variables as well on 
monoamine metabolite excretion [4.21].  
Other than the obvious complexity created by this approach in using two different 
methods to obtain data from the same sample, samples analyzed by these methods also required 
separate isolation of the DMT from blood by liquid-liquid extraction [4.19-4.20], as well as 
preparation of the samples for HPLC analysis by solid phase extraction [4.20] or protein 
precipitation/dilution [4.19]. However, recent data [4.6] show that a larger number of compounds 
in ayahuasca, as well as several previously known and potential metabolites of both DMT and 
the harmala alkaloids [4.18], also need to be monitored in blood in such studies. Given the 
increasing interest in ayahuasca and the potential for future clinical research, it was determined 
that a need existed for newer methods of analysis, an expanded list of compounds of interest, and 
simpler analytical and analyte isolation procedures.  
We report here a single methodology for the direct analysis of the known alkaloid 
components of ayahuasca as well as several known and potential metabolites of DMT and the 
harmala alkaloids in blood. The method developed is based on a 96-well plate/protein 
precipitation/filtration of plasma samples and analysis by HPLC-ion trap-ion trap-mass 
spectrometry using heated electro-spray ionization to reduce matrix effects. In the present work 
the list of compounds examined in previous studies has been expanded to include indoleacetic 




(OHDMT, 4.1.11, MeODMT, 4.1.12, potential components of ayahuasca itself), N,N-
dimethylkynuramine (DMK, 4.1.14), N-methyltryptamine (NMT, 4.1.9), 2-methyl-tetrahydro-
beta-carboline (2-MTHBC, 4.1.6) as well as a recently identified O-desmethyl-metabolite of 
THH, the major harmala component of ayahuasca, 7-hydroxy-THH (THHOH, 4.1.7; [4.22]). As 
a demonstration of its performance, the method described has also been applied to a small 
number of blood samples collected from individuals administered ayahuasca. Further, selected 
blood samples were treated with glucuronidase/sulfatase and analyzed by the same method to 
determine the presence of glucuronic acid or sulfate conjugates of ayahuasca’s major 
constituents and metabolites. 
4.2 Experimental 
4.2.1 Standards and reagents 
HPLC-grade methanol was purchased from Honeywell Burdick and Jackson (Morristown, New 
Jersey, USA). HPLC-grade water, high purity formic acid, and acetonitrile were purchased from 
J. T. Baker (Phillipsburg, NJ, USA). N-methyltryptamine (NMT), DMT, 5-hydroxy-DMT (5-
OH-DMT), 5-methoxy-DMT (5-MeO-DMT), harmine, harmaline hydrochloride dihydrate, 
harmol hydrochloride dihydrate,  harmalol hydrochloride dihydrate, indoleacetic acid (IAA) and  
N,N-diethyltryptamine (DET, 4.1.13, Table 4.1, used as an internal standard), were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Tetrahydroharmine was purchased from THC Pharm 
(Frankfurt am Main, Germany). DMT-NO and 2-MTHBC were prepared as previously described 
[4.23]. N,N-Dimethylkynuramine (DMK) was a gift from Dr. Laurent Micouin, Laboratoire de 
Chimie Thérapeutique, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France. An 
authentic reference standard of 7-hydroxy-tetrahydroharmine (THHOH) was a gift from THC 





Figure 4.1. Structures of the compounds examined in blood samples. 
 
 
        
 
         
         
 
Harmine: R1 =  CH3O, 4.1.1 
Harmol:  R1 =  OH, 4.1.2 
 
Harmaline: R1 =  CH3O, 4.1.3 
Harmalol:  R1 =  OH, 4.1.4 
 
 
THH: R1 = H; R2 = CH3; R3 = CH3O, 4.1.5 
2-MTHBC: R1 = CH3; R2 = R3 = H, 4.1.6 
THHOH: R1 = H; R2 = CH3; R3 = OH 4.1.7 
 
DMT:  R1 =  R3 = CH3; R2 =  Ø; R4 = H, 4.1.8 
NMT: R1 = CH3; R2 =  Ø; R3 = H; R4 = H, 4.1.9 
DMT-NO:   R1 =  R3 = CH3; R2 =  O
+
; R4 = H, 4.1.10 
5-OH-DMT:    R1 =  R3 = CH3; R2 =  Ø; R4 = OH, 4.1.11 
5-MeO-DMT:   R1 =  R3 = CH3; R2 =  Ø; R4 =  CH3O,  4.1.12 













Stock standard solutions (1 mg/ml) of the 14 selected compounds and of the internal 
standard (DET) were prepared individually in methanol in 10 ml amber glass vials with Teflon-
lined screw-cap closures and stored in a freezer at -20
o 
C. Working mixed standards were 
prepared in methanol at selected concentrations (0, 1, 2.5, 5, 10, 25, 50, 100, 250 500 ng/ml) by 
serial dilution and pipetted into 5 ml conical tubes. The methanol was removed by gentle 
evaporation over dry nitrogen and the residues were dissolved in amounts of 97% H2O/0.1% 
formic acid: 3% acetonitrile/0.1% formic acid mobile-phase (MP) solution corresponding to the 
appropriate sample concentrations desired.  
4.2.2 Freeze Dried Ayahuasca Administration and Plasma Collection  
Ayahuasca was prepared as an encapsulated lyophilizate obtained from a previously 
analyzed, freeze-dried and homogenized 10 L batch. One gram of freeze-dried material 
contained 8.33 mg DMT, 14.13 mg harmine, 0.96 mg harmaline, and 11.36 mg THH. A dose of 
1.0 mg DMT/kg body weight was chosen based on previous ayahuasca dosing studies [4.8, 4.21, 
4.24, 4.25].  
Subjects were 3 healthy male volunteers with previous experience with psychedelic 
drugs. The study was approved by the local ethics committee (Hospital de Sant Pau, Barcelona) 
and the Spanish Ministry of Health. Signed informed consent was obtained from all participants. 
After oral administration of 1mg/kg DMT blood was collected in10 ml EDTA tubes and 
centrifuged at 2000 rpm for 10 min at 4 ºC and the resulting plasma immediately frozen at -20 
ºC. The frozen plasma samples were stored at -80 ºC until analysis. The following time points 




h and 10 h. Samples were shipped and received on dry ice and underwent a single freeze-thaw 
cycle prior to analysis. 
4.2.3 Sample preparation 
Protein precipitation 96-well plates (Thermo Scientific, Waltham, MA, USA) were used 
to prepare the samples. Basal plasma was used for negative controls and for spiking to generate 
standard curves. Standard curve data points at 7 selected concentrations (0, 1, 2.5, 5, 10, 25, 50 
ng/ml; IAA was examined at 0, 10, 25, 50 100, 250 and 500 ng/ml) specific to the expected 
concentration range for each compound (determined from preliminary analyses) were prepared 
in blank plasma and used to examine linearity of response, to collect data for the quantification 
of samples, and to determine method performance. Spiked MP which did not go through the 
protein precipitation process was also prepared and was used to examine matrix effects and to 
determine relative analyte recovery. 
Two sets of 200 μl mixed standards in MeOH were dried completely under nitrogen and 
brought up with 200 μl of MP or 200 μl of blank plasma. To each well of a 96-well protein 
precipitation plate were added 580 μl ACN, 20 μl of 1.0 μg/ml DET (20 ng; IS) in MeOH and 
either 200 μl spiked MP (MP curve), 200 μl MP (Blank with IS), 200 μl spiked plasma (recovery 
curve), 200 μl blank plasma (matrix effects curve), or 200 μl of ayahuasca administration plasma 
sample. The plate was shaken for 3 minutes using a microplate genie (Scientific Industries, 
Bohemia, NY, USA) and then placed in a -40 
o
C freezer for 30 minutes. The protein 
precipitation plate was then placed on a Porvair Sciences (Leatherhead, UK) vacuum manifold 
with an Agilent Technologies (Santa Clara, CA, USA) 96 deep-well receiver plate placed 




The filtrate was shaken for 3 minutes and transferred to a new 96-well protein precipitation plate 
which was again placed in a -40
o 
C freezer for another 30 minutes. The protein precipitation plate 
was then placed back onto the vacuum manifold with minimum suction for 3 minutes and filtrate 
was collected in a new Agilent 96 deep well plate which was shaken for 3 minutes and then dried 
completely using a SPE Dry 96 Dual plate dyer (Argonaut, Mid Glamorgan, UK). All wells were 
brought up to 200 μl with MP. Thus, there was no relative dilution of the original sample.  
4.2.4 Determination of Matrix Effects 
Matrix effects were examined using four sets of blank plasma that were processed 
through the protein precipitation protocol and then fortified with 0, 10, 25, 50, 100, 250, and 500 
ng/ml of the 15 analytes, and samples of similarly spiked MP (n = 3) which were not processed 
through the protocol. The resulting samples were analyzed as described with 20 μl being injected 
for analysis. The data were examined to determine the slopes of the curves so generated.  The 
slopes were compared (plasma samples to one another and plasma samples to MP samples) in 
order to determine the percent relative standard deviation (%RSD) of the slopes of 
extracted/fortified plasma samples with the slopes for the MP spiked samples for each 
compound. 
4.2.5 Enzyme Hydrolysis 
A 1.0 M sodium acetate buffer at pH 5.0 was prepared by dissolving 82 g of anhydrous 
sodium acetate with 967 mL HPLC water and 33 ml of glacial acetic acid. Glucuronidase/ 
sulfatase buffer was prepared by dissolving 1 bottle (2 million units) of βglucuronidase/sulfatase 
from limpets (Patella vulgata) Type L-II  (Sigma-Aldrich, St. Louis, MO, USA) in 400 ml of 




buffer. Glucuronidase/sulfatase /acetate buffer mix (120 μl) was then added to each tube 
containing (100 μl) of individual plasma as well as 10 μl of 1.0 μg/ml DET in MP. Standard 
curves were similarly treated and prepared using 90 μl of spiked blank plasma. The samples, 
blanks, and standards were vortexed and incubated for 1 hour in a 65
o 
C shaking water bath, then 
allowed to cool to room temperature. Samples were then treated as described above for protein 
precipitation. The dilution caused by the hydrolysis process was accounted for by using 680 μl 
ACN plus 320 μl of hydrolysis mixture and bringing the final volume up to only 100 μl MP (no 
dilution of original sample). 
4.2.6 LC-HESI-MS/MS analysis 
The LC/MS/MS analyses were based, in part, on direct methods of analysis we have 
previously described for ayahuasca itself and for ayahuasca’s major constituents [4.16], as well 
as for their metabolites in urine [4.18], with modifications.  In the present study the compounds 
IAA and THHOH have been added to the analyses (as compared to [4.18]) and the internal 
standard used in the previous studies was changed from a deuterated 5-methoxy-DMT to DET. 
Furthermore, the LC mobile phase/separation system and the mass spectrometer were changed as 
was the sample preparation step.  
Thus, analyses were conducted using a Thermo Open Autosampler and a Thermo Accela 
pumping system interfaced to a Thermo Velos linear ion trap-ion trap system equipped with a 
heated electrospray ionization (HESI) probe and operated in the positive ion mode. 
Chromatographic separation was achieved on a 1.8 μm 4.6 x 50 mm (i.d.) 600 bar Agilent 
ZORBAX Eclipse Plus C18 rapid resolution HT threaded column with an Alltech Direct-Connect 




system was used as the mobile phase: A (0.1% formic acid in H20) and a mobile phase B (0.1% 
formic acid in acetonitrile) delivered at a constant flow rate of 0.3 ml/min throughout the 
analysis; A:B 97:3 (0 min)- 50:50 (14 min)- 2:98 (16 min)- 2:98 (18 min)- 97:3 (21 min)- 97:3 
(25 min), allowing for re-equilibration. The MS/MS analysis was performed using selected 
reaction monitoring (SRM) of the protonated molecular ions for the analytes and scanning the 
target ions in seven (7) different segments (Table 4.1).  The heated ESI source temperature was 
300
o 
C, sheath gas pressure was 25 psi, the auxillary gas pressure was 7 psi, the spray voltage 
(kV) was 5, the capillary temperature was 275
o 
C and the S-lens RF level was 35%. The collision 
pressure was 1.5 psi of high purity argon. Data for the molecular ions and energies utilized to 
generate diagnostic fragment ions are shown in Table 4.1.  
Detection data were collected and integration of chromatographic peaks was performed 
by Xcalibur 2.0.7 Thermo Fisher Scientific (Waltham, MA, USA) LCquan 2.5.6 QF 30115 
software.  
Identification of the compounds was based on the presence of the molecular ion at the 
correct retention time (+/- 1%), the presence of at least two transition ions, and the correct ratio 









Table 4.1: Mass spectrometric parameters for the analytes and internal standard (IS) (CE = 
collision energy in volts, v; MW= molecular weight; Product ion 1 was used for quantitation in 
every case). (Segment): Runtime in minutes (1): 5.35 (2):0.50 (3): 0.90 (4): 1.60 (5): 0.90 (6): 







































30   











30   











25   




38   




25   




25   




42   












































The concentration of compounds in blood samples was determined from the ratio of the 
peak area of the target analyte to that of the internal standard (DET), by reference to calibration 
curves prepared by spiking blank plasma samples with each of the 14 substances plus a 
consistent amount of internal standard. The transition ions used for quantitation are shown in 
Table 4.1. If the concentration observed for the actual administration samples tested was outside 
the measured range, the samples were re-analyzed after further dilution with mobile phase and 
the original concentration calculated by extrapolation. Values determined from repeated analyses 
of n aliquots of samples or standards were expressed as their arithmetic mean. For the standards 
the percent relative standard deviation (%RSD) was calculated, as was the method bias, as a 
function of concentration. Standard deviations were calculated for n determinations of samples 
as noted. Inter- and intra-assay %RSDs were also determined. Limits of detection (LOD; 
concentration response greater than 3 times baseline noise) and limits of quantification (LOQ: 
the lowest concentration having a proven %RSD of less than 15%) were also determined for each 
compound.  
To examine matrix effects, slopes were calculated for standard curves generated from 
fortifying 4 pre-extracted plasma samples and 4 water samples as described. The slope of 
individual plasma samples were compared to each other and the %RSD was determined. The 
mean of these slopes was also compared to the mean of spiked water curves and the %RSD was 






4.3 Results and Discussion 
4.3.1 Method Performance  
Each of the 15 compounds gave high yields of molecular ions (M+H)
+
 using the mobile 
phase and heated electrospray ionization parameters described. However, for many of the 
compounds the yield of a third product ion was less than 5% of the base peak and was not 
sufficient to be included in the identification criteria (Table 4.1). However, the criteria for 
identification were sufficiently rigorous [correct retention time, molecular ion plus two 
transitions, and an acceptable ratio of ions (+/- 25% absolute)] to provide high confidence in the 
data. 
Using the LC/HESI/MS/MS multi-component method described, almost all of the 15 
compounds examined were separated temporally (Figure 4.2A). All of the compounds were, 
nonetheless, completely separated by mass.  A thorough examination of ion contribution between 
each of the compounds and the masses monitored indicated that, even at the highest 
concentrations, no measurable interference (“cross-talk”) occurred. The LC method gave 
excellent peak shapes and consistency of retention time for the 15 compounds despite their rather 
diverse chemical character. Furthermore, no potentially interfering naturally occurring 
substances from plasma with the same masses and retention times were observed, in either the 
method blanks or basal samples collected from subjects. Similarly, enzyme treatment did not 
produce any new compounds that interfered with the analysis. Although this is a limited 
examination, it appears that the necessary specificity for the assay can be met, especially when 
additional parameters of ion fragmentation and ratios are also applied. A representative 




representative chromatogram for a blank plasma sample containing only the internal standard 
(DET) is shown in Figure 4.2B. A representative chromatogram from the analysis of a 
volunteer’s sample is shown in Figure 4.2C. 
Data for the retention time of each compound and their reproducibility are presented in 
Table 4.2. The calibration curves for each compound were linear over the range of 
concentrations examined (1-50 ng/ml for all compounds except IAA which was 10-500 ng/ml). 
The linear regression equations, coefficients of correlation, and the performance parameters for 
the method (% bias, %RSD, LOD, LOQ, intra- and inter-assay variation) for the 14 compounds 
using DET as the internal standard are also presented in Table 4.2. Calculations of method bias 
and %RSDs show that performing the minimal sample manipulations required in conducting 
protein precipitation/filtration result in acceptable accuracy and precision for quantitation, as 
well as the appropriateness of DET as the internal standard for all of the compounds tested. The 
modest inter- and intra-assay variations observed also reflect the method’s reliability and 
reproducibility for analysis of human blood samples after ayahuasca administration. Similarly, 
the limits of detection observed are more than adequate. Proven limits of quantitation (% bias 






Figure 4.2A. Representative chromatogram of reference standards spiked into blank plasma 
illustrating retention times and the molecular ion and product ion monitored (50 ng/ml of each; 






















Table 4.2 Continued 
  
Absolute recovery of the individual analytes was also examined (Table 4.2) and ranged 
from a mean of 59-102% (n = 8) for these 15 chemically diverse compounds compared to 
responses of equal concentrations spiked into MP and analyzed directly. Much of the loss of 
analytes appears to occur during the protein precipitation/filtration steps since the remaining 
procedures involve little more than pipetting, diluting, or drying without transfers. Because of the 




calculated but its response was observed to be linear with concentration (Table 4.2). Correction 
for endogenous IAA suggests that its recovery is greater than 90%.  
The method described has distinct advantages over previous methods used for 
determination of ayahuasca’s major components in blood in that a greater number of relevant 
compounds can be monitored, only a single analysis is required, and sample manipulation is 
minimal. 
4.3.2 Matrix Effects 
Matrix effects were assessed by comparing the linear regression line slopes of standards spiked 
into MP over a range of concentrations versus standards similarly spiked into 4 blank plasma 
samples after being processed through the protein precipitation protocol (n = 4 for each) and by 
comparing the slopes for the compounds spiked into extracted plasmas from individuals to each 
other [4.26, 4.27]. Table 4.3 shows the %RSD for the slopes of standards spiked into pre-
extracted plasma and water. Comparing the slopes of the 4 plasmas to each other, a %RSD of 
15% or less was observed for all compounds. This suggests that little variability will be observed 
in conducting patient-to-patient plasma analyses due to matrix effects and that standard curves 
derived from spiking blank plasma will likewise provide appropriate results. Comparing the 
slopes for the compounds spiked into extracted plasma to the slopes for the same compounds 
spiked into water, a %RSD of less than 15% was also obtained for all compounds except for 
DMK. This suggests that some matrix effects occur for this compound but, in terms of attaining 
accurate quantitation, they may be overcome by fortification into blank plasma. There was little 
variability or deviation from linearity for standards spiked in water or in different plasma 




response, and the accuracy of the results was readily reproduced over a broad range of 
concentrations (Table 4.3). Similarly, shifts in retention times were not evident, regardless of the 
relative concentrations of the standards (Table 4.1). Thus, the use of a HESI probe, which has 
been shown to greatly diminish matrix effects [4.26-4.29], as well as the overall methodology, 
provides an accurate, sensitive and specific analysis, apparently unaffected by co-eluting or other 
interferences.  
Table 4.3. Matrix effects. The slopes of the individual plasma samples, pre-extracted and 










Table 4.4. Mean (n =6) concentrations (ng/ml) of ayahuasca components and metabolites 
detected in plasma from three (3) volunteers. 
 
4.3.3 Analysis of Administration Samples 
Representative chromatograms for the detection and quantitation of the ayahuasca 
alkaloids and metabolites present in plasma samples collected before and after administration are 
presented in Figures 4.2(B and C), respectively. Tabulation of the concentrations of these 
compounds in samples from three individuals is shown in Table 4.4. Enzyme treatment of a 
selected volunteer’s samples did not show any significant increase in any of the major alkaloids 
or their metabolites (data not shown). Considering that conjugates have been observed in urine 
[4.22], their absence in plasma suggests that they are rapidly excreted. 
In the three individuals’ samples examined, DMT concentrations were observed to be 
lower at all time points than the major DMT metabolite recently identified in human urine [4.18], 
DMT-NO. This metabolite was observed to be present in the plasma at 3-to-4 times the 
concentration of DMT itself, peaking at 1.5 hrs after ayahuasca administration at approximately 
45 ng/ml. The formation of the N-oxide appears to occur rapidly after ayahuasca administration.  
Enzymes responsible for this conversion may be N-oxidases in blood as well as liver or kidney 
CYPs (cytochrome P450 superfamily) [4.23, 4.30-4.34]. Others have reported DMT-NO to be a 
major metabolite of DMT in rat plasma and urine [4.31-4.34]. The present study is the first 




inhibition of MAO-A in rats, such as occurs with the harmala alkaloids in ayahuasca [4.35], 
shifts the normal metabolism of DMT to IAA to the formation of the N-oxide in vitro and in vivo 
[4.31-4.34]. It may be assumed that a similar mechanism is at work following ayahuasca 
administration to humans. Nonetheless, rather modest levels of DMT continue to be observed 
and are consistent with previous studies of ayahuasca pharmacokinetics [4.11, 4.19-4.21]. 
For the major harmala components, THH was observed to peak in the 4.5 hr samples with 
concentrations greater than 55 ng/ml. THH is the major harmala component of ayahuasca and it 
is also the major harmala excretion product in urine in man [4.6, 4.18]. Harmalol and harmol as 
well as THHOH, harmaline, harmine, and 2-MTHBC were also detected in most samples. 5-OH-
DMT, a potential component of some ayahuasca preparations, and NMT, a known demethylation 
metabolite of DMT, were randomly detected and no 5-MeO-DMT, another potential component 
of ayahuasca, was observed.  The compound DMK, a DMT metabolite reported to be formed in 
human blood in vitro [4.36], was not detected. This was also the case in our examination of urine 
samples collected from humans administered ayahuasca [4.18], and suggests that, while this 
compound was identified in in vitro studies, apparently it is not a metabolite of DMT in vivo in 
man. 
Despite the MAO inhibiting effect of the harmala alkaloids [4.25, 4.35, 4.37], significant 
increases in the plasma levels of IAA were observed following ayahuasca administration. The 
reason for this observation is, at present, unclear. However, the data suggest that, to the degree 
that MAO inhibition and a resultant shift to N-oxide formation occur, a significant quantity of the 






 The present method expands the list of compounds capable of being monitored in blood 
following ayahuasca administration in humans while providing a simplified approach to their 
analysis. The characteristics of the method suggest that its sensitivity, specificity, and 
reproducibility are adequate for future clinical research with ayahuasca. The results also show for 
the first time that the major DMT urinary metabolite, DMT-N-oxide, is also a major circulating 
product in the blood following ayahuasca administration. Thus, the method and data provide the 
most complete profile of DMT, harmala alkaloids, and their respective metabolite concentrations 
in the blood following ayahuasca administration to date. 
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Chapter 5. Summary and Conclusions 
5.1 Summary and Conclusions 
In the research presented in this dissertation we have established, expanded, and modified 
an analytical method which we applied to study various ayahuasca samples and urine or blood 
samples before and following administration of ayahuasca to humans. This method has proved 
useful in the study of ayahuasca in human and ethnobotanical research, and examinations of 
ayahuasca preparations or human samples. The characteristics of the methods suggest their 
sensitivity, specificity and reproducibility are adequate for use in further toxicological and 
clinical research on ayahuasca as well as functioning as a potential assay to screen biological 
samples for endogenous hallucinogens. 
In chapter 2 we presented a manuscript describing the development of a liquid 
chromatography–electrospray ionization-tandem mass spectrometry procedure capable of the 
simultaneous quantitation of 11 of the major alkaloid components of ayahuasca, including 
several known and potential metabolites. This method affords rapid detection of alkaloids by a 
simple dilution assay requiring no extraction procedures while demonstrating an extremely high 
degree of specificity for the compounds in question, as well as lower limits of detection and 
quantitation than reported by previous methods while also eliminating potential matrix effects. 
The major components present in ayahuasca were identified as THH and harmine, followed by 
DMT and harmaline with quantities appearing very similar to those reported by others. The 
samples were also examined for the presence of DMT-NO which, to our knowledge, represented 
the first such effort to assay for this compound in ayahuasca preparations. Although a major 





After establishing the method we applied the assay to 11 ayahuasca samples collected by Dr. 
Leanna Standish in either North or South America as presented in the manuscript contained in 
Appendix A. DMT, harmine, harmol and tetrahydroharmine concentrations among ayahuasca 
teas made and used in healing ceremonies in South or North America were remarkably similar. 
Concentrations of two of the three minor beta-carbolines (harmaline and harmalol) were 
statistically different. North American tea samples were higher in harmaline and harmolol 
suggesting that the tea formula made and used in North America may include a higher ratio of B. 
caapi vine relative to P. viridis leaves or possibly a different strain of B. caapi. Seasonal, growth 
and or methodological practices could also account for some differences. 
We were able expand the method to include a number of potential metabolites and modify 
the preparation protocol in order to make the method suitable to analyze urine samples from 
participants before and after they had consumed a freeze dried form of ayahuasca thanks to the 
help of our collaborator Dr. Jordi Riba whose lab collected the samples. This manuscript was 
presented as Chapter 4: the overall major metabolite observed was DMT-NO, peaking at 4-8 h 
after ayahuasca administration with concentrations of approximately 11 µg/ml representing the 
first report of DMT-NO as a metabolite of DMT in the urine of humans and suggesting that N-
oxidation may represent a major metabolic route for DMT clearance in humans, particularly if 
MAO becomes inhibited, such as occurs with ayahuasca administration. DMT-NO could also 
represent a major in vivo metabolite of DMT and thus, may serve as a better marker for 
endogenous DMT production and metabolism in mammals. THH represented the major 
component in the 8-24 h samples, with concentrations greater than 5 µg/ml. However, following 
enzyme hydrolysis harmol and harmalol were found to be at far higher concentrations compared 




fold increase in the amount of harmol, making harmol the most abundant product excreted in 
urine. DMK did not appear to be consistently excreted in urine, even with MAO inhibition. 
However; it remains possible that this compound undergoes metabolism to another, as yet 
undetermined, compound prior to excretion. 
Next we modified and expanded the method to make it appropriate for the analysis of blood 
plasma samples following freeze-dried ayahuasca administration as presented in Chapter 4. The 
method expanded the list of compounds capable of being monitored in blood following 
ayahuasca administration in humans while providing a simplified approach to their analysis. The 
results also demonstrated for the first time that the major DMT urinary metabolite, DMT-NO, 
was also a major circulating product in the blood following ayahuasca administration. DMT-NO 
was observed to be present in the plasma at 3-to-4 times the concentration of DMT itself, 
peaking at 1.5 h after ayahuasca administration at approximately 45 ng/ml. THH was observed to 
peak in the 4.5 h samples with concentrations greater than 55 ng/ml. THH thus represented the 
major harmala component of ayahuasca and also the major harmala excretion product in urine 
and plasma in man. Despite the MAO inhibiting effect of the harmala alkaloids, significant 
increases in the plasma levels of IAA were observed following ayahuasca administration. The 
reason for this observation remains unclear. However, the data suggest that a significant quantity 
of the administered DMT may still be converted to IAA. The method applied and the resulting 
data provide the most complete profile of DMT, harmala alkaloids, and their respective 
metabolite concentrations in the blood following ayahuasca administration to date. 
In a recent study we applied our established blood method and collaborated with Rafael 
Santos and Dr. Jordi Riba’s lab on a study entitled ‘Autonomic, Neuroendocrine, and 




published in December 2011 in the Journal of Clinical Psychopharmacology. This study was not 
included here as it constituted part of the dissertation of one of Dr. Riba’s students (Santos). 
Nonetheless, we found that ayahuasca led to measurable DMT plasma levels and distinct 
subjective and neurophysiological effects that were absent after amphetamine. Prolactin levels 
were significantly increased by ayahuasca but not by amphetamine, and cortisol was increased 
by both, with ayahuasca leading to the higher peak values. Natural killer cells were also 
increased by both. These findings indicate that ayahuasca has a moderate impact on the nervous 
system with a modulatory capacity on cell-mediated immunity [B.25]. If present, endogenous 
DMT and -carbolines could also potentially produce these effects. 
In a follow up to our preliminary urine study where we established the urine method in 
Appendix B, we presented a manuscript further characterizing the metabolism and disposition of 
DMT and harmala alkaloids after oral administration of ayahuasca. O-demethylation plus 
conjugation seems to represent an important but probably not the only degradation route for the 
harmala alkaloids in humans. Harmol and harmalol concentrations were 10-fold and 5-fold the 
amounts ingested with ayahuasca demonstrating, that the vast majority of harmol and harmalol 
recovered in urine after ayahuasca ingestion must necessarily be formed through the metabolic 
breakdown of harmine and harmaline. The recoveries of each harmala alkaloid plus its O-
demethylated metabolite varied greatly between 9 and 65%. 
N-oxidation appears to represents a major degradation pathway of DMT in humans when 
administered together with -carbolines in ayahuasca suggesting the existence of an alternative 
metabolic route to biotransformation by MAO. Less than 1% of the administered DMT dose was 
recovered as the unmetabolized parent compound. The main DMT metabolite found in the urine 




around 10%. DMT and metabolite excretion was maximal during the first third of the 24 h 
collection period. DMT-NO made up around 20% of the compounds measured. Recovery of 
DMT plus metabolites reached 68%. These findings support the notion that MAO plays a 
prominent role in the degradation of DMT. However, MAO-inhibition after ayahuasca appeared 
to be either incomplete or short-lived, as large amounts of IAA were already detected in the first 
4 h collection interval. Partial inhibition of MAO by the harmalas in ayahuasca appeared to be 
sufficient to allow psychoactive effects. DMT-NO does not seem to function as an intermediate 
during the formation of IAA by MAO-A, but it does appear to represent the major metabolite of 
DMT in the absence of or after inhibition of mitochondrial MAO. MAO inhibition could 
consequently shift metabolism from oxidative deamination to N-oxidation as a compensatory 
metabolic mechanism. 
Future investigations could address the metabolism of oral DMT in humans without the 
presence of -carbolines, in order to assess the contribution of the different metabolic pathways 
for its degradation under physiological conditions. This would allow us to estimate the degree of 
metabolic compensation induced by the harmala alkaloids in ayahuasca. We have already 
collected and analyzed preliminary data for this study which compared urine samples from 
participants following orally administered or smoked DMT. Alternatively no studies have yet 
pretreated humans with MAO inhibitors alone and measured the parent compounds and their 
corresponding N-oxides. The advantage of such a study would be that the N-oxide, as opposed to 
the indoleacetic acid, retains the original structure of the parent molecule, permitting a 
cumulative association. Therefore, monitoring the N-oxide metabolites rather than the parent 
compounds alone in MAO-inhibited humans could provide a substantial advantage in detecting 




humans could substantially enhance detection and quantitation of endogenous hallucinogenic 
compounds in the periphery, especially if the N-oxide metabolites are monitored. It would appear 
necessary that in order to sufficiently detect parent compounds sensitivity of assays must be 
improved to 1.0 pg/ml or less and include more frequent sampling and longer collection times 
given the possible intermittent presence of these compounds in the periphery, blood and urine. 
In this regard, much of our interest in ayahuasca pharmacology and metabolism was 
based on the need to further understand the possible role and needed methods of analysis for 
endogenous psychedelics and to provide a more definitive answer to the question, “Are 
‘hallucinogenic’ tryptamines naturally present in human metabolism?” In Appendix C this 
question was addressed, and we concluded that the quantity of mass spectral evidence in the 
literature demonstrated that DMT and 5-OH-DMT do indeed appear endogenously and may be 
sufficiently measured in human body fluids although the tissue sources of these compounds in 
human remains unknown. The highest levels of INMT mRNA have been reported in adrenal 
gland and lung, although no large amount of INMT mRNA was detectable in brain [C.96, C.97].  
The active transport of DMT across the blood-brain barrier [C.98] suggests that peripheral 
synthesis may still affect central function. A fluorescent antibody to INMT and confocal 
microscopy [C.99], have identified INMT in spinal cord, brain, retina, and pineal gland, and 
suggest the future possibility for mapping and characterizing the regulation of the endogenous 
psychedelic pathway. Future molecular biological approaches and advances in assay 
methodology could potentially help characterize the biochemistry and physiology of these 
compounds in humans. Data regarding psychodynamics, concentrations, circadian variation, 
metabolism and clearance as assessed by validated analytical methods applied to biological 




psychophysiology. We propose that future studies assay CSF, blood and urine and monitor for 
DMT, 5-OH-DMT, 5-MeO-DMT and their corresponding N-oxides using validated mass 
spectrometric methodology. Pretreatment of study subjects with an MAO inhibitor could 
optimize results. 
 The search for endogenous psychedelic tryptamines could also turn toward solid organs 
such as adrenal, brain, lung, pineal, retina, and other tissues in which INMT activity has been 
demonstrated. Mapping of INMT within certain cell types and locations could reveal its 
intracellular distribution and possible associations with various receptors. The creation of an 
INMT knockout mouse and characterization of the phenotype could also greatly aid in 
understanding the role of this enzyme and endogenous psychedelics.  
  Why might organisms produce endogenous psychointegrative substances such as DMT 
and 5-MeO-DMT? The current research conducted leaves this question open to speculation and 
hypotheses, which abound. Could DMT represent a molecular interface to the experience of 
consciousness? Indeed, there are many hypotheses that have attempted to link our more mundane 
experiences of the world to the more extraordinary psychic states through quantum mechanical 
mechanisms and the possibilities of a multidimensional reality beyond normal perception. These 
quantum mechanical-to-cosmological hypotheses appear to be untestable at present. However, it 
may not necessarily remain this way. Perhaps further study of these molecules which have been 
claimed to afford the capability of perceived transport to “other worlds” might help answer some 
of these questions and expand our knowledge of the origins of religious and mystical states and 
other extraordinary states of consciousness. Perhaps these molecules function as dynamic 




sensation, emotions, cognition, intuition, inspiration and intention. Perhaps they afford an 
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The purpose of this study was to compare the concentrations of psychoactive alkaloids 
present in ayahuasca teas used in healing ceremonies conducted in South and North America.  
Ayahuasca, an ethnobotanical medicine used by indigenous peoples of South America for 
thousands of years, is primarily derived from the synergistic interactions of two Amazonian 
plants, Psychotria viridis and Banisteriopsis caapi.  The leaves of P. viridis contain the alkaloid 
N, N-dimethyltryptamine (DMT).  The woody vine of B. caapi contains three main active indole 
alkaloids, beta-carboline alkaloids, harmine, tetrahydroharmine (THH) and harmaline [A.1]. 
Ayahuasca tea is a unique serotonin agonist with both short and long-term action that, with 
repeated use, modifies 5-HT receptor sites to increase serotonin availability. DMT contained in 
ayahuasca tea is a potent serotonin agonist at the 5-HT1A presynaptic and 5-HT2A post-synaptic 
membrane receptor sites [A.1, A.2] and possibly increases neocortical GABA levels [A.4].  
DMT is believed to be primarily responsible for the psychoactive effects of ayahuasca.  
Orally administered DMT is metabolized by an enzyme in the gut and liver, monoamine oxidase 
A (MAO-A) before it can cross the blood-brain barrier.  Inhibition of MAO by beta-carbolines 
present in ayahuasca tea protects DMT from oxidative deamination in gut and liver , thus 
enabling DMT to be active when administered orally [A.2, A.5].  
Beta-carbolines are tricyclic indole alkaloids that are structurally related to tryptamines and 
have been identified in both plant and mammalian tissue [A.6]. The primary mechanism of 
action of two of the three principal beta carbolines found in ayahuasca, harmine and harmaline, 
is the reversible inhibition of MAO-A, which is responsible for breaking down serotonin, 
dopamine and norepinephrine [A.3]. The third beta carboline, tetrahydroharmine weakly inhibits 




We sought to measure the concentration of nine known active alkaloid constituents present in 
ayahuasca tea:  N,N-dimethyltryptamine (DMT), 5-OH-DMT (bufotenine)  and N-
methyltryptamine (precursor of DMT) from the P. viridis plant and six beta-carbolines (harmine, 
harmol, tetrahydroharmine, harmalol, harmaline and tetrahydroharmol (THHO)) from the B. 
Caapi vine [A.3, A.7]. 
A.2 Materials and methods 
A.2.1 Materials 
Eleven ayahuasca tea samples were collected from two regions, South America (N=6) and 
North America (N=5).  Five ayahuasca ceremony leaders were approached to provide research 
samples of the tea used in a ceremony that had been conducted within the previous 24 hours.  
Each of the ayahuasqueros approached agreed and 10 ml of the tea was collected into sterile 
brown glass vials then immediately frozen at -80 degrees C until batch analysis.  Eleven samples 
were provided to the researchers. Six of the tea samples were brewed by traditional 
ethnomedicine methods in South America (N=6) and five samples from non-denominational 
ayahuasca ceremonies brewed and conducted on the Hawaiian Islands or in the mainland U.S.  
South American samples differed from the North American samples by level of freshness of the 
tea decoction.  South American samples were shipped from indigenous groups in the Amazon 
basin to the ayahuasquero ceremony leader and thus were not as fresh as those made for 
ceremonies conducted in Hawaii and on the U.S. mainland. 
A.2.2 Methods 
The concentration of nine known - constituents of each sample of ayahuasca tea were 




tandem mass spectroscopy methods developed by our research team and performed at the 
Louisiana State University in a single-blind manner; see  [A.7] for detailed methods.  In brief, 
standard solutions of the 9 compounds analyzed were prepared using a 10 ppm stock standard in 
MeOH stored in -80
o
C. A 1.0 ml aliquot of this solution was dried under nitrogen and brought up 
with 1.0 ml 97/3 (water + 0.1% formic acid: acetonitrile +0.1% formic acid) mobile phase (MP). 
This 10 ppm stock solution in 97/3 MP was then serially diluted to 5ppm, 2.5ppm, 1ppm, 
500ppb, 250ppb, 100ppb, 50ppb, 25ppb, 10ppb, 5ppb, 2.5ppb, and 1 ppb with MP. 
Extracts were prepared and analyzed in duplicates. For all the ayahuasca extracts 50 μl of each were 
diluted with 950 μl MP (=20x dilution) in a 96 well Thermo protein precipitation plate (PPT), then 
shaken for 3 minutes on an orbital shaker. The samples were then transferred to a second PPT using a 
vacuum manifold, shaken again for 3 minutes and then placed again on a vacuum manifold. Vacuum was 
applied for 5 minutes with the filtrate being collected in a 96 well deep-well plate from which the samples 
were injected for analysis. 
To 180 μl aliquots of the 9 compound mix-serial dilutions (5ppm-1ppb) were added 20ul of 1 ppm 
DET internal standard in a separate Thermo PPT plate. Similarly, 100 ul aliquots of the 20X diluted 
samples were mixed with 100 ul of 1 ppm DET and 800 ul MP in a Thermo PPT plate, shaken for 3 
minutes, placed on the vacuum manifold and again suctioned with minimal vacuum for 5 minutes. 
Standards were treated in the same manner. The filtrate was collected into a new 96 well deep-well plate 
and 20 ul were injected for analysis. 
Analyses were conducted in duplicate and as described in [A.7] with two modifications; the mobile 
phase conditions for LC separation were slightly altered to afford improved separation of the target 
compound, as described in [A.8]  and the instrument used was a Thermo Velos ion trap  [A.8] as opposed 




We evaluated whether concentration of the nine alkaloids present in the 11 ayahuasca tea 
samples was related to the concentration of any of the other eight active constituents measured in 
this study in two ways, first as a simple correlation then in a regression model.  T-tests were used 
to detect statistically significant difference in alkaloid concentrations between ayahuasca made in 
South versus North America.  Correlations and regression models were used to investigate the 
relationship among the nine alkaloids.  Principle components analysis was used to detect the 
effect of geographic location (South versus North American) tea samples. 
A.3 Results 
A.3.1 DMT and 5-OH-DMT concentrations in ayahuasca teas 
 DMT concentrations vary widely but there were no differences in mean DMT 
concentration between South and North American ayahuasca tea samples. Nine alkaloid 
constituents were measured in each of 11 tea samples. See Table A.1 for raw data, mean and 
standard deviation for the South American samples (N=6) and North American samples (N=5).  
DMT concentrations ranged from 0.26 – 0.78 mg/ml, a 3 fold difference in concentration across 
all 11 samples. However, there were no significant differences between the mean DMT 
concentration between North (0.49 mg/ml + 0.18) and South (0.45 mg/ml + 0.71) American teas.   
Higher levels of 5-OH-DMTwere found in South American samples (p= 0.048) compared to 
North American samples (Table A.2). 
DMT concentration among ayahuasca teas made and used in healing ceremonies in South 
America or North America are remarkably similar in concentrations of the main psychoactive 




Concentrations of two of the three minor beta-carbolines (harmaline and harmalol) were 
statistically different. North American tea samples were higher in harmaline and harmalol.  
Table A.1.  Concentration of Major Alkaloid Constituents in Ayahuasca Teas Collected in 




A.3.2 DMT, harmine, THH and harmol concentration 
Figure A.1 shows the mean concentration of the four alkaloids found in highest concentration in 
ayahuasca teas made in South and North America: DMT, harmine, THH and harmol.   None of 


























AY025 Brazil Brazil Barquinha Church 0.260 1.302 0.049 0.765 1.084 0.000 0.020 0.008 0.000
AY003A3 Peru US Mainland Shipibo 0.646 1.406 0.064 0.656 1.159 0.004 0.000 0.008 0.000
AY009A3 Peru US Mainland Shipibo 0.371 2.512 0.223 2.070 1.657 0.030 0.127 0.025 0.005
AY010A3 Peru US Mainland Shipibo 0.277 2.028 0.172 1.872 1.467 0.021 0.116 0.021 0.003
AY011A3 Peru US Mainland Shipibo 0.413 2.004 0.157 1.475 1.427 0.026 0.077 0.018 0.006
AY024 Peru US Mainland Shipibo 0.708 2.423 0.178 1.580 1.598 0.023 0.080 0.017 0.004
N=6
Mean 0.446 1.946 0.141 1.403 1.399 0.018 0.070 0.016 0.003
Std. Deviation 0.189 0.503 0.069 0.577 0.232 0.013 0.051 0.007 0.002
North America
AY001B3 Hawaii Hawaii Non-denom 0.317 1.706 0.281 1.877 1.293 0.002 0.081 0.022 0.001
AY005B3 Hawaii Hawaii Non-denom 0.784 2.343 0.315 1.898 1.717 0.000 0.036 0.023 0.000
AY026 Hawaii US Mainland Non-denom 0.393 1.114 0.215 1.441 0.980 0.000 0.045 0.016 0.000
AY027 Hawaii US Mainland Non-denom 0.524 2.063 0.348 2.137 1.612 0.002 0.052 0.027 0.000
AY020 Hawaii Hawaii Non-denom 0.425 3.916 0.228 2.116 2.743 0.007 0.097 0.031 0.000
N=5
Mean 0.489 2.229 0.277 1.894 1.669 0.002 0.062 0.024 0.000




















Figure A.1.  Mean concentration in mg/ml of DMT, harmine, THH and harmol in 
ayahuasca teas made for ceremonial use in South American (n=6) compared to North 
American (n=5).  There were no significant differences. 
 
A.3.3 Beta-carboline alkaloid concentrations in ayahuasca teas 
 The six beta-carbolines from the B. caapi vine were measured in the 11 ayahuasca tea 
samples and ranked by greatest to least concentration present in each tea sample.  In South 
American teas harmine > harmol > THH > harmaline > THHO > harmalol.  In North American 
teas harmine > THH > harmol > harmaline > THHO > harmalol.   Harmine was found in highest 
concentration in all of the South American samples and three of the five North American 
samples.  However, there were no statistical differences in mean harmine concentration between 
South (1.95 + 0.51) and North American (2.23+ 1.05) tea samples (Table A.2).    
Concentrations of the minor beta-carboline alkaloids present in ayahuasca (harmaline, 




(harmine, harmol and THH). There was more variability in the minor beta-carbolines among tea 
samples. For example, harmaline varied widely among all 11 samples, ranging from 0.049 – 
0.348 (a 7 fold difference). Harmaline was found in higher concentrations in North American 
versus South American samples and this difference was statistically significant (p = 0.006).  
Higher levels of harmalol were found in South America than in North American samples 
(p=0.029). There were no significant differences in concentrations of the other beta-carbolines, 
harmine, harmaline, THH, Harmol, or THHO.   
 
Table A.2. Comparison of active constituents of ayahuasca tea samples from South 
America versus North America using T tests. 
 
 South America North America  t P 
DMT 0.4459 0.4888 -.382 0.711 
Harmine 1.9457 2.2286 -.589 0.571 
Harmaline 0.1406 0.2773 -3.551 0.006 
THH 1.4031 1.8938 -1.728 0.118 
Harmol 1.3988 1.6691 -.936 0.374 
Harmalol 0.0175 0.0021 2.942 0.029 
THHO 0.0699 0.0623 .301 0.770 
NMT 0.0163 0.0237 -1.972 0.080 
5-OH DMT 0.0028 0.0003 2.511 0.048 
 
 
A.3.4 Bivariate and multivariate relationships among the 11 ayahuasca alkaloids 
  Because the DMT present in ayahuasca tea derives only from the P. viridis plant 
admixture, we did not expect, nor detect, any significant correlations of DMT with the 
concentration of the beta-carbolines measured.  Concentrations of 5-OH-DMT or N-





Table A.3 shows that there were no significant bivariate relationships between DMT and 
any of the other eight alkaloids present in ayahuasca, including 5-OH-DMT. This later result is 
surprising in that DMT and 5-OH-DMT are constituents in P. viridis and might be expected to 
co-vary.  However, a regression where DMT is the dependent variable and the other eight 
alkaloid constituents as predictors turned out to be significant in that, other things being 
controlled, harmaline and harmalol had both a positive predictive relationship with DMT.  
Higher DMT concentrations were associated with higher harmaline and harmalol, which are two 
of the less significant beta carbolines present in ayahuasca tea.  DMT levels did not correlate 
with concentrations of the major beta-carbolines, harmine, harmol or THH.  There were also 
marginal significant negative relationships between NMT and DMT, and 5-OH-DMT with DMT 






Table A.3. Correlations of DMT concentration with the other eight alkaloid constituents 
present in 11 ayahuasca tea samples 
 
  Harmine Harmaline THH Harmol Harmalol THHO NMT 5-OH-DMT 
DMT r .168 .228 -.018 .163 -.108 -.387 -.003 -.123 
p .621 .501 .958 .632 .753 .239 .993 .719 





Table A.4. Regression coefficients where DMT is the constant dependent 







t  P B Std. Error Beta 
 (Constant) .283 .199  1.422 .291 
Harmine -.239 .386 -1.034 -.619 .599 
Harmaline 8.656 1.868 4.563 4.634 .044 
THH -1.040 .422 -3.013 -2.468 .132 
Harmol 1.167 .745 3.117 1.567 .258 
Harmalol 31.401 5.947 2.141 5.280 .034 
THHO 4.165 3.036 .935 1.372 .304 
NMT -81.934 24.015 -3.257 -3.412 .076 
5-OH-DMT -94.689 26.626 -1.180 -3.556 .071 
     
 
To better understand the relationships among the nine active constituents of ayahuasca 
teas collected from 11 ceremonies, we performed a Principal Component Analysis ( PCA), 
which produced a map to determine how closely related were  the samples and their relationship 









Figure A.2.  Principal Components Analysis of 11 ayahuasca tea samples collected in either 
South or North America. Red represents the nine alkaloids.  Green represents the North 
American samples and Yellow represents   the South America samples.  North American 
samples tend to fall on the upper left quadrant, the South American tend to fall at the upper right 
or lower middle of the map. Component 1 (geographical location of ceremony) and component 2 
(psychoactive alkaloid concentrations) describe the 11 samples well.  Geographical location 
(South versus North America) and psychoactive alkaloid concentrations, account for 76.2% of 
the variability.  
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We compared results from our 11 samples to results published by Callaway et al (1996) 
[A.9] who measured DMT, harmine, harmaline and THH in an ayahuasca tea used in a União do 
Vegetal Church ceremony (UDV) in the Brazilian Amazon rain forest near Manaus [A.8].  The 
UDV ayahuasca tea contained DMT at 0.24 mg/ml, harmine at 1.7 mg/ml, harmaline at 0.2 
mg/ml and THH at 1.07 mg/ml. The 11 samples measured in the current study that were 
collected from 2000-2011 had a higher average concentration of DMT (0.47 + 0.18) compared to 
the 1996 data, but had similar concentrations of the beta-carbolines harmine (2.1 + 0.77 mg/ml), 
harmaline (0.21 + 0.09 mg/ml) and tetrahydroharmine (1.63 + 0.51 mg/ml). 
A.4 Discussion  
Given the variation between South America and Hawaii in climate, seasonality of harvest 
and variations in ayahuasca tea formulas used cross-culturally, we expected to observe greater 
differences in concentration of the major known active constituents.  Mean concentrations of 
DMT, the main psychoactive alkaloid present in ayahuasca tea, did not differ between South and 
North American tea samples.  Concentrations of the major beta-carbolines (harmine, harmol and 
THH) also did not statistically differ between South and North American samples.  
Of the eight beta-carbolines measured in the 11 tea samples, only harmaline and harmalol 
concentrations significantly differed. Harmaline was nearly two-fold higher in North American 
tea samples suggesting that relatively more B. caapi vine is added to the decoctions made in 
North America compared to South America.  However, this conclusion is complicated by our 
data showing that harmalol, a low concentration beta-carboline present in B. caapi, was found in 
much higher average concentration (nine-fold) in South American samples.   Concentrations of 




The difference between South and North American ayahuasca tea samples may be due to 
variations in season of harvest, strain and maturity of plant used, climate, tea recipe used, and 
freshness of decoction. North American samples were decocted within 24 hours of the time that 
the sample was frozen.  We do not have information regarding the data of decoction of Brazilian 
or Peruvian samples. 
A.5 Conclusions 
DMT concentration among ayahuasca teas made and used in healing ceremonies in South 
America or North America are remarkably similar in concentrations of the main psychoactive 
alkaloids present in ayahuasca tea (DMT, harmine, harmol and tetrahydroharmine).   
Concentrations of two of the three minor beta-carbolines (harmaline and harmalol) were 
statistically different. North American tea samples were higher in harmaline and harmolol 
suggesting that the tea formula made and used in North America may include a higher ratio of B. 
caapi vine relative to P. viridis leaves or possibly a different strain of B. caapi.  Seasonal, growth 
and or methodological practices may also account for some differences. 
A.6 Future Ayahuasca Characterization Publications 
We have further collaborated with Dr. Standish using the established ayahuasca method on 
two future ayahuasca characterization publications and two studies preparing ayahuasca for 
clinical trials. The data for these studies has already been collected and analyzed and the 
manuscripts are currently in the process of being written. The first examined anatomical 
distribution of DMT in P. viridis and beta-carbolines in B. caapi and was conducted by Reardon, 
McIlhenny, Barker, and Standish. We found no DMT present in B. caapi in any anatomical 




base of the leaves, still less in petiole, and the least amount was found in the woody vine. 
Interestingly the traditional brewing of ayahausca only included the vine of B. caapi and no parts 
of the leaf were included. Both the leaf and meristematic nodes in P. viridis contain DMT at 
similar levels. 
 The second characterization study was a comparison of psychoactive alkaloids in 
ayahuasca tea formulations that varied in P. viridis and B. caapi weight ratios conducted by 
Standish, Reardon, McIlhenny, and Barker. We found that systematic increase of P. viridis and 
B. caapi weight ratios from 1:2 to 1:16 resulted in a fairly linear curve of ratio to concentration 
of harmine while DMT concentrations remained fairly constant. 
A.7 Future Publications to Prepare Ayahuasca for Clinical Trials 
The first study intended to prepare for potential ayahuasca clinical trials examined chemistry, 
manufacturing and controls and was conducted by Standish, Martzen, Reardon, McIlhenny, and 
Barker. We found that ayahuasca alkaloid concentration and therefore dose potency can be 
controlled by decocting the two plants separately then recombining and that ayahuasca extracts 
are stable when stored as there appears to be no loss of DMT or harmine after 12 months of 
refrigeration or freezing at - 80
o
C. It was further observed that ayahuasca can also be sterilized 
by lyophilization or autoclave without loss of psychoactive alkaloids and that the experimental 
ayahuasca extracts examined were free of heavy metals. 
The second clinical preparation was an ayahuasca dose consideration for planning a phase I 
dose escalation safety and tolerability study in healthy adults and was conducted by Standish, 
Reardon, Martzen, McIlhenny, and Barker. We asked the question: What Phase I doses should be 




down to at least 833 ml to result in a potent ayahuasca extract that would be similar to what has 
been used as traditional medicine: 833 ml to provide 16 doses at 50 ml volume per dose. Dosing 
may start at DMT 0.025, 0.05, 0.10, 0.25. 0.50, and 1.0 mg/ml. Since harmine posed fewer safety 
concerns we will retain the same concentration of harmine at 1.5 mg/ml. Extracts may be made 
with B. caapi vine 3-5 cm in diameter cut fresh within one week and refrigerated from time of 
harvest to time of decoction. Extracts may be made with distal P. viridis leaves until we know 
DMT concentration in mature leaves. Extracts can be sterilized using 0.22 micron filtration and 
placed into 100 ml sterile brown bottles for freezing until administration when the extract will be 
removed from the freezer and rendered liquid again in a dedicated secure refrigerator. 
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Appendix B. Metabolism and disposition of N,N-dimethyltryptamine and 
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Ayahuasca is a psychotropic plant tea obtained from the stems of the jungle liana 
Banisteriopsis caapi and usually the leaves of Psychotria viridis or Diplopterys cabrerana [B.1, 
B.2]. The tea is used by many Amazonian peoples to attain a modified state of consciousness, 
which is a central element of rites of passage, religious ceremonies and shamanic medicine [B.2]. 
In recent years, the firmly established ancestral uses of ayahuasca have given way to new forms 
of consumption. Syncretic religious groups using ayahuasca as a sacrament have appeared and 
have expanded their activities to the urban areas of South America and also to Europe and North 
America. An increasing number of foreigners travel to the Amazon to participate in ayahuasca 
retreats and traditional healers travel to Europe to organize ayahuasca ceremonies. The growing 
attention ayahuasca is attracting worldwide has raised public health concerns [B.3]. 
The powerful psychotropic effects of ayahuasca arise from the pharmacological 
interaction between the β-carboline alkaloids present in B. caapi and the tryptamines found in P. 
viridis and D. cabrerana. On the one hand, the β-carbolines, mainly harmine, harmaline and 
tetrahydroharmine, are reversible inhibitors of the enzyme monoamine-oxidase A (MAO-A) 
[B.4, B.5]. On the other hand, P. viridis and D. cabrerana contain DMT [B.5], a potent 
psychedelic [B.6-B.8], which is a priori not active orally [B.7] due to extensive first pass 
metabolism by MAO-A. Both the β-carbolines, also known as harmala alkaloids, and the DMT 
present in the plants are extracted into the ayahuasca infusion and ingested by users [B.9]. The 
blockade of visceral MAO brought about by the β-carbolines is believed to render DMT orally 
active, allowing its access to systemic circulation and subsequently to the central nervous system 
[B.10]. There, DMT interacts with serotonergic 5-HT2A, 5-HT1A and 5-HT2C and other 









Early studies involving the administration of pure DMT to humans had already observed 
that it lacked psychoactive effects after oral administration [B.7]. Following parenteral DMT, 
Szára failed to find the unmetabolized drug in urine and identified indole-3-acetic acid (IAA), 
formed by oxidative deamination, as the drug's degradation product [B.6]. Kaplan and coworkers 
found that following an intramuscular injection, DMT disappeared from plasma very rapidly. 
They reported that less than 0.1% was recovered in 24 h urine but they did not attempt to identify 
the putative metabolites [B.18]. 
The role of MAO in the metabolic breakdown of DMT has been stressed in the literature 
based in the aforementioned presence of IAA in urine after DMT and in the efficacy of the 
harmala alkaloids and other MAO-inhibitors to render DMT psychoactive per os [B.19]. 
However, oxidative deamination by MAO may not be the sole metabolic pathway in humans. In 
vitro and animal studies have described N-oxidation, N-demethylation and cyclization as 

















To date no study has addressed the fate of DMT and the harmala alkaloids when 
administered in combination in ayahuasca. In a preliminary assessment conducted by our group 
in the course of analytical method validation, DMT-N-oxide (DMT-NO) and harmol and 
harmalol, the O-demethylation products of the harmine and harmaline, respectively, were 
detected in the urine and blood of three individuals after ayahuasca intake [B.23, B.24]. The 
present manuscript describes the assessment of the metabolism and urinary disposition of DMT 
and the harmala alkaloids in a group of healthy volunteers following ayahuasca administration. 
B.2 Materials and Methods 
B.2.1 Volunteers 
Ten young healthy male volunteers were recruited. Participants were experienced 
psychedelic drug users. The most commonly used substances were psilocybin mushrooms and 
LSD, followed by ketamine, peyote and mescaline. None of the participants had used ayahuasca 
before. Volunteer mean age was 29.0 years (range 20-38); mean weight was 67.0 kg (range 60-
85); and mean height was 1.77 m (range 1.69-1.96). Volunteers underwent a structured 
psychiatric interview (DMS-IV) to exclude current or past history of Axis-I disorders and 
alcohol or other substance dependence. General good health was confirmed by medical history, 
laboratory tests and ECG.  
The study was conducted in accordance with the Declarations of Helsinki and Tokyo 
concerning experimentation on humans, and was approved by the hospital's ethics committee and 





Ayahuasca was administered orally as an encapsulated lyophilizate. The freeze-dried 
material was obtained from a Brazilian batch of ayahuasca and contained 8.33 mg DMT, 14.13 
mg harmine, 0.96 mg harmaline and 11.36 mg tetrahydroharmine (THH) per gram. The 
lyophilizate was also tested for harmol and harmalol and was found to contain 0.30 mg/g harmol 
and 0.07 mg/g harmalol. Freeze-dried ayahuasca was administered in doses equivalent to 1.0 mg 
DMT/kg body weight.  
B.2.3 Study Design and Sample Collection 
Urine samples were obtained in the course of a clinical trial involving three experimental 
sessions. In a double-blind crossover balanced design, participants received in each experimental 
session one of the following treatments: a lactose placebo, 20 mg d-amphetamine, and 1.0 mg 
DMT/kg body weight ayahuasca. In addition to urine collection, the study involved the 
measurement of various pharmacodynamic parameters including subjective, neuroendocrine and 
immunomodulatory data. A detailed description of the methods used and the results concerning 
these variables have been published elsewhere [B.25]. In the present article we report only the 
data obtained from the analyses of urine samples collected following ayahuasca administration. 
The amounts of harmine, harmaline and tetrahydroharmine recovered in urine are reported 
together with the amounts of their potential O-demethylated metabolites, harmol, harmalol and 
tetrahydroharmol (7-hydroxy-tetrahydroharmine). Samples were also analyzed for DMT and its 
potential biotransformation products IAA, DMT-NO, N-methyltryptamine (NMT) and 2-methyl-
tetrahydro-betacarboline (2MTHBC). Additionally, samples collected after placebo 
administration were also quantified for IAA, which is known to be excreted under normal 




the following time intervals relative to ayahuasca (and placebo) administration: 0-4h, 4-8h, 8-16h 
and 16-24h. The collected urine volume at each time interval was noted, the pooled urine was 
well mixed and 50 ml aliquots were separated and stored at -80 ºC until analysis. Samples 
underwent a single freeze-thaw cycle prior to analysis. Samples were analyzed with and without 
enzyme hydrolysis. Enzyme hydrolysis was achieved using β-glucuronidase/sulfatase from 
limpets (Patella vulgata) Type L-II (Sigma-Aldrich, St. Louis, MO, USA) as described by 
McIlhenny and coworkers [B.23]. 
B.2.4 Analytical Method 
Urine sample analyses were conducted by the methods of McIlhenny and coworkers, 
which uses HPLC with electrospray ionization and tandem mass spectrometry [B.23]. Thus, 100 
µl of well mixed urine were diluted to a volume of 1.0 ml (900 µl of LC mobile phase; 97:3 
water with 0.1% formic acid:acetonitrile with 0.1% formic acid) and filtered [B.23]. A volume of 
10 µl was injected for the analysis. 
The LC/MS/MS method had been validated for the determination of the following 
compounds: DMT, IAA, DMT-NO, NMT, 5-hydroxy-DMT, dimethylkynuramine, 2MTHBC, 5-
methoxy-DMT, harmine, harmaline, tetrahydroharmine, harmol, harmalol and tetrahydroharmol. 
Thus, analyses were conducted using an Agilent 1200 series LC system (Agilent Technologies, 
Palo Alto, CA, USA) equipped with an Agilent G1367A HiP ALS autosampler, an Agilent 
G1311A Quaternary micropump, and an Agilent G1332A degasser. An Agilent G131gA TCC 
column oven operating at 25o °C was interfaced to a TSQ Quantum Access 1.5 SP1 tandem MS 
(Thermo Fisher Scientific, Waltham, MA, USA) with electrospray ionization (ESI) operated in 




Chromatographic separation was achieved on a 1.8 m 4.6 x 50 mm (i.d.) Agilent 
ZORBAX Eclipse Plus C18 rapid resolution HT threaded column with an Alltech Direct-
Connect Column 2 m pre-filter (Deerfield, IL, USA) using gradient elution. The MS/MS 
analysis was performed using selected reaction monitoring (SRM) of the protonated molecular 
ions for the analytes. The spray voltage was 4000 V, sheath gas (nitrogen) pressure 50 psi, 
capillary temperature 310o °C, and collision pressure was 1.5 psi. of high purity argon. 
Generation of detection data and integration of chromatographic peaks were performed by 
Xcalibur 2.0.7 Thermo Fisher Scientific (Waltham, MA, USA) LCquan 2.5.6 QF 30115 
software.  
Identification of the compounds was based on the presence of the molecular ion at the 
correct retention time, the presence of three transition ions and the correct ratio of these ions to 
one another (+/- 25% relative). The proven limit of quantitation (LOQ) was 5 ng/ml for all 
compounds. The limits of detection for the compounds examined were comparable to results 
previously attained, [B.23] ranging from 0.07 ng/ml for DMT-NO to 0.57 ng/ml for harmol. 
Tetrahydroharmol was observed to have a LOD of 0.17 ng/ml. 
B.2.5 Statistics 
 Descriptive statistics (mean and standard deviation) were used to report the amounts of 
the different compounds measured. Percentage recoveries were calculated relative to the amount 
of parent compound administered. Differences in percentage recoveries between enzymatically-
treated and non-treated samples were analyzed using paired-samples t-tests. Pearson's correlation 
coefficient was used to explore potential linear relationships between measures. All comparisons 




Table B.1: Mean (SD) DMT and metabolite amounts excreted in each collection interval. 
Amounts are expressed as micrograms (g) and micromoles (mol). Percent recovered relative 
to the administered DMT dose. Percent recoveries were compared using paired samples t-tests 






Table B.2: DMT and metabolite amounts measured for each study participant in 24h urine in the absence 
(Non-Enz.) and presence (Enzyme) of enzymatic hydrolysis. Percent values refer to the total amounts 














Table B.3: Mean (SD) amounts of excreted harmala alkaloids and their metabolites. Amounts 
are expressed as micrograms (g) and micromoles (mol). Percent recovered relative to the 
respective parent comound, i.e, harmine for harmol, harmaline for harmalol and 
tetrahydroharmine for tetrahydroharmol. Percent recoveries were compared using paired samples 





B.3 Results and Discussion 
 Mean (SD) urine volume collected was 1632 (519) ml after placebo and 1535 (366) ml 
after ayahuasca. These volumes did not differ statistically [t(9)=0.62]. Mean excreted creatinine 
was 5537(1368) mg/dl after placebo and 6525(1303) mg/dl after ayahuasca. Despite the larger 
values after ayahuasca, differences were not statistically significant [t(9)=-2.02, p=0.074]. 
After placebo administration, concentrations for all measured compounds were below the 
LOD (limit of detection) except for IAA.  
The amounts of DMT and its potential metabolites measured at the different collection 
intervals are presented in Table B.1. To control for physiological IAA, amounts after placebo 
have been substracted from amounts after ayahuasca. As shown in the table, less than 1% of the 
administered DMT dose was recovered as the unmetabolized parent compound. Recovery was 
significantly less following enzymatic treatment. This may be due to degradation of DMT 
produced by heating and hydrolysis (1 hr at 65°C) [B.23]. The main DMT metabolite found in 
the urine was IAA, the oxidative deamination product obtained from the MAO pathway. 
Recovery was increased after enzymatic treatment, although the difference was not statistically 
significant. The second highest concentration metabolite detected was DMT-NO, with recoveries 
around 10%. Another 0.2% was made up by 2MTHBC and NMT. The cyclization product 
2MTHBC accounted for 0.13-0.16% of the administered DMT dose. Enzymatic treatment 
increased the amount of NMT by a factor of 1.5.  
DMT and metabolite excretion were maximal during the first third of the 24h collection 




excreted, 68/66% of all measured IAA, 88/88% of all measured DMT-NO, 57/60% of all 
measured 2MTHBC and 73/77% of all measured NMT were excreted. 
In order to address the relative contribution of oxidative deamination and of MAO-
independent metabolism, mainly N-oxidation, to the biotransformation of DMT, we performed 
additional calculations. In addition to calculating the percentage of each metabolite relative to 
administered DMT dose, we assessed the percentage relative to the overall DMT plus 
metabolites recovered in urine. This way we controlled for potential individual differences in 
DMT absorption. Table B.2 shows the amounts of DMT and metabolites found in 24h urine for 
each participant expressed in micromoles and percentage. As shown therein, IAA was roughly 
80% of all substances measured. Individual values were as low as 43% and as high as 88%. 
DMT-NO made up around 20% of the compounds measured, varying between 10% and 50%.  
Potential linear relationships between excreted DMT, DMT-NO and IAA were explored. 
We had hypothesized that an inverse relationship might exist between the amounts of DMT-NO 
and IAA excreted. However, no statistically significant correlation was found.  
Results for the harmala alkaloids and their metabolites are shown in Table B.3.  THH was 
the most abundant alkaloid in urine followed by harmaline and harmine, both prior to and after 
enzymatic treatment. Relative to the respective administered dose, the highest recovery rates 
were found for harmaline and THH. Recovery for harmine was two orders of magnitude lower. 
Enzymatic treatment caused a threefold increase in the amount of recovered harmine. However, 
this procedure decreased the amounts of recovered harmaline and THH. 
Before enzymatic treatment, the most abundant O-demethylated product in urine was 




obtained for harmalol. Following enzymatic hydrolysis with glucuronidase/sulfatase, large 
increases were seen in the measured amount of these three compounds. A near 50-fold increase 
in the amount of harmol was observed. Harmalol levels were increased by a factor of 3 and 
tetrahydroharmol by a factor of 1.5.  Thus, the degree of conjugation varied greatly from one 
metabolite to another. Whereas only 2% of harmol was present in free form, free harmalol was 
36% and free tetrahydroharmol was as high as 68%. The combined recoveries of harmine plus 
harmol, harmaline plus harmalol and THH plus tetrahydroharmol after enzymatic treatment were 
approximately 28%, 65% and 9%, respectively.  
Given that the ayahuasca used in the study contained small amounts of harmol and 
harmalol, we calculated also the percent recoveries of these two compounds relative to the 
amounts present in the tea. The obtained values were 1028% for harmol and 516% for harmalol, 
that is 10-fold and 5-fold the amounts ingested with ayahuasca. These figures show that the vast 
majority of harmol and harmalol recovered in urine after ayahuasca ingestion must necessarily 
be formed through the metabolic breakdown of harmine and harmaline. These calculations could 
not be performed for tetrahydroharmol because the analytical standard for this compound was 
not available prior to the start of the clinical trial, when the ayahuasca batch was analyzed for 
alkaloid content. Analyses of other preparations of ayahuasca have indicated, however, that 
tetrahydroharmol is not present in such extracts (preliminary data, Barker). 
Disposition of the harmala alkaloids and their metabolites was more evenly distributed 
throughout the 24h collection period than that of DMT and its breakdown products. In the first 
eight hours after dosing, 53/45% of all measured harmine (free/total) was excreted. Lower 




Consistent with these differences, recovery in the first 8h was 68% for total harmol, 47% for 
total harmalol and 44% for total tetrahydroharmol.  
No statistically significant correlations were found between the amounts of harmala 
alkaloids and their metabolites in 24h urine and the amounts of DMT and its metabolites 
recovered. 
 The amounts of -carbolines recovered in the global 24h collection period expressed in 
micromoles were used to compute the following metabolic ratios: harmol/harmine, 
harmalol/harmaline and tetrahydroharmol/tetrahydroharmine. Statistically significant 
correlations were found between them: harmol/harmine vs. harmalol/harmaline, r=0.800, p<0.01; 
harmol/harmine vs. tetrahydroharmol/THH, r=0.803, p<0.01; harmalol/harmaline vs. 
tetrahydroharmol/THH, r=0.967, p<0.001.  
These metabolic ratios were also tested for correlations with excreted DMT, DMT-NO, 
IAA and the metabolic ratios IAA/DMT and DMT-NO/DMT. However, no statistically 
significant results were found. 
In the present study we assessed the urinary disposition of ayahuasca alkaloids and their 
metabolites following administration of a lyophilized sample of the tea to humans. In line with 
previous findings after intramuscular administration [B.18], DMT was found to undergo 
extensive metabolism, with less than 1% being detected unchanged in urine and increased IAA 
excretion.  
Early investigations in humans had found lack of psychoactivity when pure DMT was 




found IAA as a degradation product of DMT in urine [B.6]. A more recent study assessing 
human plasma concentrations of DMT following its i.v administration found DMT to be 
measurable in blood at 30 minutes but almost undetectable at 1h [B.27]. Our present findings 
support the notion that MAO plays a prominent role in the degradation of DMT, as previously 
noted by other researchers [B.21-B.22, B.28-B.32]. However, MAO-inhibition after ayahuasca 
appears to be either incomplete or short-lived, as large amounts of IAA were already found in the 
first four hour collection interval. Partial inhibition of MAO by the harmalas in ayahuasca 
appears to be sufficient to allow psychoactive effects. 
Another interesting finding is that MAO-catalyzed oxidative deamination is not the only 
metabolic pathway available to DMT when administered together with the β-carbolines in 
ayahuasca. We found DMT-NO to be a major metabolite accounting for 20% of all tryptamine 
derivatives measured in urine and 10% of the administered DMT dose. The cyclization product 
2MTHBC and the N-demethylation derivative NMT were also found. Studies with pure 
tryptamines and tryptamine derivatives, including DMT, 5-MeO-DMT, and 5-OH-DMT, have 
found oxidative deamination by MAO-A to be a major metabolic route in brain, liver and kidney 
in vitro, producing the corresponding indoleacetic acid [B.32-B.35]. IAA has been identified in 
both rodent [B.35] and human urine [B.6] following DMT administration but the amount 
recovered represented only 2.7% and 8.3%, respectively of the dose administered, with no 
detectable DMT being observed. In another study, 
[14C]
-IAA was identified as the major 
metabolite representing up to 23% of the radioactivity in the blood of rabbits 60 min after i.v. 
injection of 
[14C]
DMT. However, the majority of radioactivity, and thus other possible 




In line with our findings after ayahuasca, in vitro studies have shown that other pathways 
besides oxidative deamination also contribute to DMT metabolism. Studies of DMT metabolism 
in vitro have identified DMT-NO as a major NADH dependent metabolite using mouse liver 
homogenates [B.20], liver microsomal fractions from rabbits [B.37], as well as rat brain 
homogenates [B.21]. Two of these studies also identified NMT as a metabolite of DMT [B.21, 
B.37]. N-oxidation has also been identified as an important metabolic pathway of DMT in vivo 
[B.31], while N-demethylation seems to function as a minor degradation route [B.31]. NMT 
could also act as a substrate for MAO and become further metabolized to IAA. Cyclization to 
form the beta-carboline species 2-MTHBC has also been shown to be an alternative metabolic 
pathway in vivo and in vitro [B.21, B.38]. 
DMT-NO does not seem to function as an intermediate during the formation of IAA by 
MAO-A but it does appear to represent the major metabolite of DMT in the absence of or after 
inhibition of mitochondrial MAO [B.20, B.30]. MAO inhibition could consequently shift 
metabolism from oxidative deamination to N-oxidation and the above mentioned alternative 
routes as a compensatory metabolic mechanism. Sitaram’s group demonstrated that iproniazid 
inhibited the formation of IAA from DMT in liver homogenates although not the formation of 
DMT-NO [B.32]. Iproniazid was found to increase the levels of DMT in vivo in rat brain, liver, 
kidney and blood as well as DMT-NO in rat liver [B.31], and urinary excretion of unmetabolized 
DMT, DMT-NO and NMT [B.30]. In the present study we found a 80:20 ratio for IAA:DMT-
NO after ayahuasca. A future study could address the metabolism of DMT in humans after oral 
administration without the harmalas and evaluate whether this ratio is shifted toward lower 




 The -carbolines appeared to also undergo extensive metabolism with low urine 
recoveries. Harmine appeared to be the most metabolically labile of the three, as only 0.1% of 
the parent compound was recovered unchanged. In agreement with previous research that had 
shown harmine and harmaline to undergo O-demethylation [B.39-B.42], we found large amounts 
of harmol and harmalol in urine. These findings are in line with results from a clinical study 
involving oral dosing with ayahuasca and in which these compounds were measured in plasma 
[B.17]. More recently, harmol and harmalol were found in urine in a three subject sample 
following ayahuasca intake [B.23]. Enzymatic treatment of the samples in the present study 
showed that most harmol and harmalol was excreted as sulfate and glucuronide conjugates, as 
previously found by McIlhenny and coworkers [B.23]. Here we also found for the first time that 
tetrahydroharmol, the O-demethylation product of tetrahydroharmine, is also formed in vivo 
following ayahuasca.  
Recoveries of each harmala alkaloid plus its O-demethylation product were lower than 
expected. Whereas harmaline+harmalol in urine accounted for 65% of the total harmaline dose 
administered with ayahuasca, harmine+harmol only reached 28% of the administered parent 
comopound; and percentage recovery for THH+tetrahydroharmol was as little as 9%. A potential 
explanation is that THH undergoes an intense first pass effect and does not reach systemic 
circulation. Although low plasma concentrations have been observed for harmine after oral 
administration of ayahuasca [B.17], THH levels in blood have consistently been found to be 
quite high [B.17, B.43]. A plausible alternative explanation is that the harmalas, and particularly 
THH, are degraded by other metabolic routes. In this respect, various hydroxylated metabolites 
have been described following incubation of harmine in mouse liver microsomes [B.40]. Despite 




calculated metabolic ratios in the present study showed a high degree of correlation, suggesting a 
common enzymatic route for the O-demethylation of the parent compounds. 
B.4 Conclusion 
To conclude, the present results show that N-oxidation is also a major degradation 
pathway of DMT in humans when administered together with -carbolines in ayahuasca. This 
finding demonstrates the existence of an alternative metabolic route for biotransformation by 
MAO. Also, that O-demethylation plus conjugation is an important but probably not the only 
degradation route for the harmala alkaloids in humans. Finally, we propose that future 
investigations address the metabolism of oral DMT in humans in the absence of -carbolines, in 
order to assess the contribution of the different metabolic pathways to its degradation under 
physiological conditions. This would allow us to estimate the degree of metabolic "shift" induced 
by the harmala alkaloids in ayahuasca.  
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 Three indole alkaloids that possess differing degrees of psychotropic/psychedelic activity 
have been reported as endogenous substances in humans. These compounds, all metabolites of 
tryptophan, are N,N-dimethyltryptamine (DMT, C.1.1, Figure C.1), 5-hydroxy-DMT 
(bufotenine, HDMT, C.1.2) and 5-methoxy-DMT (MDMT, C.1,3). Their presence has been 
reported in human cerebrospinal fluid (CSF), urine, and/or blood utilizing either paper and/or 
thin layer chromatography (TLC), direct ultraviolet (UV) or fluorescence (Fl) measurements, gas 
chromatography (GC) using various sensors (nitrogen-phosphorous detector [NPD]; electron 
capture detector [ECD]; mass spectrometry detector [MSD]), high-performance liquid 
chromatography (HPLC) using UV and/or Fl detection, HPLC-radioimmunoassay, HPLC-
electrochemical detection, and liquid chromatography/tandem mass spectrometry (LC/MS/MS) 
(Tables C.1-C.3, references [C.1-C.69]). Indeed, the review of the 55 year history of the 
development of methodology for the analysis of these compounds shows how closely it has 
paralleled the evolution of analytical technology itself, with each researcher seeking more 






Figure C.1. Structures of the compounds discussed. 
 A renewed interest in these compounds as naturally occurring substances in humans has 
occurred, in part, due to DMT’s recent characterization as an endogenous substrate for the 
ubiquitous sigma 1 receptor [C.70] and for its possible action at trace amine receptors [C.71]. In 
both cases, the roles of DMT and the receptors themselves in regulating some aspect(s) of human 
physiology are poorly understood. Given their known psychedelic effects, there remains an 
interest in their possible role in naturally occurring altered states of consciousness such as 
psychosis, dreams, creativity and imagination, religious phenomena and even near-death 
experiences [C.72]. Although the vast majority of research into the presence of these compounds 
sought their role in mental illness, no definitive conclusions yet exist. A determination of the role 
of these compounds in humans awaits further research, much of which awaits the development 




 Interest in DMT has also increased because of the burgeoning use and popularity of the 
religious sacrament ayahuasca which contains DMT and several harmala alkaloids, which serve 
to make DMT orally active. Ayahuasca tourism in South America and the establishment of 
syncretic churches using ayahuasca as a sacrament [C.73, C.74] have stimulated research into the 
mechanisms of its effects and its possible use as a therapeutic [C.75]. The resumption of human 
research characterizing DMT’s psychopharmacology [C.76-C.84] and the ongoing use of pure 
DMT for therapeutic and recreational purposes have also focused interest on this and related 
psychedelics. The dimethylated-tryptamines (DMTs) increasing visibility within medical, non-
medical, religious and/or recreational contexts [C.75] reinforce the importance of determining 
their endogenous role. 
 This review addresses several fundamental issues regarding these three endogenous 
psychedelics. For example, are DMT, HDMT and/or MDMT truly present in humans [C.85]? 
Early criticisms of reports of endogenous psychedelics were directed at the fact that rather non-
specific chemical tests were being applied, double-blind analyses were not always being 
performed and dietary or medication sources were not always adequately ruled out as responsible 
for the identifications [C.2, C.12]. Further, it was claimed that possible artifacts produced from 
the extraction solvents and conditions of analysis may have led to misidentification of the DMTs 
in some early studies [C.20] and, more recently, that the use of halogenated solvents in the 
analysis may have affected their detection [C.86]. Biological factors that may have affected the 
detectabilty of these compounds in the periphery were also acknowledged, which included their 
rapid metabolism [C.87, C.88]. Finally, there have been concerns that the studies searching for 
their presence and an association with specific clinical disorders have failed to understand and 




 To address these issues we have undertaken a critical review of 69 published studies 
reporting the detection or detection and quantitation of these compounds in human body fluids. 
In reviewing this literature, we address the methods applied and the criteria used in the 
determination of the presence of DMT, MDMT, and HDMT. We begin with the original report 
of the presence of bufotenin (HDMT) in human urine in 1955 using paper chromatography [C.1] 
and end with the most recent report concerning the presence of bufotenin (HDMT) in human 
urine using LC/MS/MS [C.69].  
 We will be addressing the following questions; How valid were early studies regarding 
the presence and/or quantities of these compounds in human cerebrospinal fluid (CSF), blood 
and/or urine? Were the analytical methodologies and the identification criteria adequate? Are 
they truly there? When present, are they of dietary origin? When and where in the human body 
are they produced? Can we influence their detection in biological samples by pharmacologically 
inhibiting their metabolism by monoamine oxidase (MAO). How does turnover rate and 
metabolism of these substances influence their detectabilty? Have the precursors and/or 
metabolites of these compounds been adequately monitored? Is monitoring these compounds in 
biological samples such as CSF, blood and/or urine the best, or even most practical way to 
determine their role? What will such data tell us about the function of these compounds? Where 
does the research on endogenous psychedelics go from here? 
C.2 Historical Perspective 
 The search for endogenous psychedelics soon followed the discovery of the psychedelic 
effects of mescaline and lysergic acid diethylamide (LSD) in humans. Observations of these 
effects gave rise to hypotheses that they were related to the symptomology observed in a 




[C.92]. It was proposed that schizophrenics may biochemically produce similar compounds as 
“schizotoxins” [C.93]. A search for mescaline-like compounds proved unrewarding [C.94], but 
in studies examining urine samples for serotonin-like compounds, researchers reported in 1955 
[C.1] and 1956 [C.2] the presence of 5-hydroxy-N,N-DMT (HDMT, bufotenin) in humans. 
Subsequently, Axelrod (1961) [C.95] reported the presence of an enzyme capable of N-
methylating indole-ethylamines and producing DMTs. Following these reports, attention began 
to focus in earnest on the possible endogenous formation of the indole-ethylamine psychedelics. 
During the next fifty years many studies reported finding DMT, HDMT and/or MDMT in human 
CSF, urine and/or blood. Most of these studies sought differences in levels between controls and 
psychiatric, especially psychotic, patients. Some studies claimed higher concentrations and 
significant differences in levels between the groups; some reported not finding the compounds at 
all in either patients or controls.  
 It is of interest to note that in its original conception, the schizotoxin hypothesis proposed 
that the formation of an endogenous psychedelic schizotoxin would be an aberration of 
metabolism and that “normals” would not form such compounds [C.92]. However, numerous 
studies subsequently reported finding one or more of these compounds in controls as well as 
patients. Despite many such efforts, there has yet to be demonstrated a definitive link between 
the blood and/or urine levels of these compounds and any psychiatric diagnosis [C.85, C.93].  
 The earliest studies (1950s-1960s) in the search for endogenous psychedelics applied the 
technology available at the time. These were mainly paper and thin-layer chromatography (TLC) 
using different reagents as visualization (color development) sprays, as well as comparing Rf 
values with spotted standards as the criteria for identification. In 1967, thin-layer spots were 




chromatography (GC) using a flame-ionization detector (FID) [C.21].  In this case, Rf values 
from TLC and relative retention time (Rt) from GC that were consistent with known standards 
served as the confirmation criteria. Subsequent studies applied this technology utilizing other 
detectors, such as nitrogen-phosphorous, electron capture and, eventually, mass spectrometry 
(MS). In many of these studies the sole criterion for identification was retention time compared 
to a reference standard. However, in the case of the early MS data, the presence of a single major 
fragment ion [C.38] (m/z 58 ) or one or two minor ions [C.39], served as additional confirmation. 
Liquid chromatography with UV and fluorescence detection was also applied, with the collected 
peaks being confirmed by GC/MS in some cases. As the analytical technology evolved, so too 
did the methods applied to detect and measure the compounds of interest, with resultant gains in 
sensitivity, specificity and validity.  
 The most recent methods have applied LC/MS/MS technologies in combination with 
more stringent confirmation criteria [C.67-C.69].  These criteria are based on specific protonated 
molecules, fragment ions and their ratios to one another, and on relative retention times. 
However, as the criteria have become more exacting and the specificity of the methodology has 
improved, detection of the endogenous psychedelics appears to have become less frequent and, 
where detection has occurred, at significantly lower concentrations than originally reported. 
 Tables C.1-C.3 are a compilation of 69 studies directed toward detecting or detecting and 
quantitating the three indole psychedelics--DMT, HDMT, and MDMT--in human (patient and/or 
control) CSF, blood, and/or urine. The entries for each study were taken from copies of the 
original publications. In some cases, the published studies neglected to address the relevant 





Table C.1; Review of 69 studies regarding endogenous psychedelics showing the year, reference, 
compounds analyzed, type of sample and method of extraction. Acronyms and abbreviations; IV, 
intravenous; HNMT, 5-hydroxy-N-methyltryptamine; ext, extraction; vol, volume; w/wo, with or 
without; evap, evaporate; ppt, precipitate; sat., saturated; TLC, thin-layer chromatography; cent, 





























Table C.2; Review of 69 studies regarding endogenous psychedelics showing the year, reference, 
compounds analyzed, detection methods, limits of detection (LOD) and confirmation criteria. 
Acronyms and abbreviations; HNMT, 5-hydroxy-N-methyltryptamine; TLC, thin-layer 
chromatography; 2-D, two dimensional; GC-FID, gas chromatography-flame ionization detector; 
derive, derivative; HFBI, heptafluoro-butyryl-imidazole; IS, internal standard; HPLC, high 
performance liquid chromatography; ESI, electrospray ionization; MS, mass spectrometry; ND, 
not determined; RT, retention time; UV, ultraviolet; TI, total ion; m/z, mass-to-charge ratio; CI, 
























Table C.3; Review of 69 studies regarding endogenous psychedelics showing the year, reference, 
compounds analyzed, the subjects (patients and controls), the results positive or negative out of 
the total (i.e, 4/12) and the concentrations of the compounds observed. Acronyms and 
abbreviations; HNMT, 5-hydroxy-N-methyltryptamine; meds, medications; MAOI, monoamine 
oxidase inhibitor; admin, administration; schizo, schizophrenia; neg, negative; ND, not detected; 






























C.3 Study Review 
 69 studies were reviewed. Other studies that do exist were either not accessible through 
current abstract search engines, were sufficiently obscure as not to be abstracted, or were 
not available in a translated form for inclusion in this analysis. Articles were obtained 
through SciFinder (Chem Abstracts Selects; https://scifinder.cas.org) and PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) database searches. 
C.3.1 HDMT: urine 
 51 studies examined urine samples for HDMT (27 assayed urine for HDMT only). 
Taking into account the presence of the 5-hydroxyl group on HDMT, 7 studies 
specifically addressed the issue of the excretion of HDMT as a conjugate by using 




approximately 50% of the total HDMT is excreted as a glucuronide conjugate. The 
remaining 44 studies did not conduct hydrolysis or enzyme treatment and thus did not 
determine the total amount of HDMT excreted but rather free HDMT alone. 
 1,912 individuals’ urine samples were assayed; 1,249 patients (predominantly diagnosed 
with schizophrenia) and 663 controls. Among patients 886 were positive for HDMT 
(71%) and 363 were negative. Among controls 363 were positive for HDMT (55%) and 
300 were negative. Thus, 1,249 individuals were positive (65%) and 663 were negative. 
Most of the urine samples were obtained from 24 hour collections with varying quantities 
of the total collection being used for analysis. However, many other studies only used 
morning or random samples, while a few used 8 or 12 hour collections.  Varying amounts 
of urine were used in the assays, based on volume or total mg creatinine. The range of 
extraction techniques is shown in Table C.1 and the analytical approaches employed are 
shown in Table C.2. One study examined and failed to find a diurnal variation in urine 
concentrations of HDMT [C.50], while another reported that HDMT excretion did not 
vary diurnally but rather was intermittent [C.64]. Several studies examined dietary 
influences on detection of HDMT but none established a dietary source (Table C.3). 
 Concentrations of HDMT were usually reported as µg/24 hours while other studies 
reported concentrations as µg/g or µg/mg creatinine, nmol or pmol/ml or per 24 hours, 
and ng/ml or µg/L. Using the most common methods of reporting, these studies 
demonstrated concentrations ranging from 1 to 62.8 µg/24 hours, and from 0.48 to 218 
ng/ml.  
C.3.2 HDMT: blood 




 240 individuals’ blood samples were examined; 166 patients and 74 controls. Plasma, 
serum, and whole blood were used. A single study provided 146 of these total samples 
[C.67]; it used a limit of detection of 0.3 ng/ml and a 1.0 ml sample of plasma or serum 
for analyses. For all of the studies combined, 4 patients were positive for HDMT (2.4%) 
and 162 were negative. Eighteen controls were positive for HDMT (24%) and 56 were 
negative. Thus, a total of 22 individuals were positive for HDMT (9%) in blood and 218 
were negative. One study reported higher concentrations of HDMT were obtained from 
extraction of whole blood compared to serum [C.52]. 
 When concentrations were reported (rather than simply present or not present) the 
concentrations of HDMT in blood ranged from 22 pg/ml (HPLC-radioimmunoassay) 
[C.52] to 40 ng/ml (direct fluorescence assay of extracts) [C.11]. 
C.3.3 HDMT: cerebrospinal fluid 
 None of the 69 studies examined CSF for HDMT. 
C.3.4 DMT: urine 
 Of the 69 studies, 29 examined urine for DMT. 
 There were 861 individuals’ urine samples examined: 635 patients and 226 controls. 
Among patients, 276 were positive for DMT (43%) and 359 were negative. Among 
controls, 145 were positive (64%) and 81 were negative. Thus, a total of 421 individuals 
were positive for DMT (49%) in urine and 440 were negative. Most of the urine samples 
were 24 hour collections and analytical samples varied in volume. However, many also 
used morning or random samples, while a few used 8 or 12 hour collections.  Various 
amounts of the urine were used in the assays, based on a set volume of urine or that 




shown in Table C.1 and analytical approaches employed are shown in Table C.2. Several 
studies examined dietary influences on detection of DMT and were uniformly negative 
(Table C.3). One study reported that DMT and NMT (N-methyltryptamine; C.1.4, Figure 
C.1) concentrations in urine were stable when stored at -15oC for up to 90 days [C.50]. 
 Concentrations of DMT were usually reported as µg/24 hours while others used µg/g or 
µg/mg creatinine, nmol/ml or pmol/ml nmol/24 hours, pmol/24 hours, ng/ml or µg/L, etc. 
Concentrations ranged from 0.02 to 42.98 +/- 8.6 (SD) µg/24 hours, and from 0.16 to19 
ng/ml. 
C.3.5 DMT: blood 
 Of the 69 studies, 11 examined blood for DMT. 
 417 individuals’ blood samples were examined for the presence of DMT: 300 patients 
and 117 controls. Blood samples used were plasma, serum and/or whole blood. Among 
patients 44 were positive (15%) and 256 were negative.  A single study is responsible for 
137 of these negative samples [C.68]; the authors--who used a 1.0 ml sample of plasma 
or serum--reported a limit of detection of 0.2 ng DMT/ml. Among controls 28 were 
positive (24%) and 89 were negative. Thus, a total of 72 individuals were positive for 
DMT (17%) in blood and 345 were negative. The range of extraction methods used is 
shown in Table C.1 and analytical approaches employed are shown in Table C.2. One 
study demonstrated that higher concentrations of DMT were found by extracting whole 
blood rather than using plasma [C.52]. One study demonstrated that there was no 
difference in DMT blood levels between venous and arterial blood [C.54]. One study 
reported that DMT concentrations were stable in plasma when stored for 60 days at 6oC 




 When concentrations were reported (rather than simply present or not present) the 
concentrations of DMT in blood ranged from 51 pg/ml (HPLC-radioimmunoassay) 
[C.52] to 55 ng/ml (direct fluorescence assay of extracts) [C.11]. 
C.3.6 DMT; cerebrospinal fluid 
 Of the 69 studies, 4 examined CSF for DMT. 
 A total of 136 individuals’ CSF samples have been examined for the presence of DMT; 
82 patients and 54 controls.  Among patients 34 were positive for DMT (41%) and 48 
were negative. Among controls 22 were positive (41%) and 32 were negative. Thus, 56 
individuals were positive (41%) and 80 were negative. 
 Concentrations of DMT in CSF ranged from 0.12 to100 ng/ml (Table 3). 
C.3.7 MDMT: urine 
 Of the 69 studies, 9 examined urine for the presence of MDMT. 
 A total of 113 individuals’ urine samples were examined: 94 patients and 19 controls. A 
single study was responsible for 65 of these samples [C.67].  Combining all studies, two 
patients were positive for MDMT in urine (2%) and 92 were negative. Two controls were 
positive (10.5%) and 17 were negative. 
 The concentrations of MDMT in urine ranged from 0.3 to 1.3 ng/ml (HPLC-
radioimmunoassay) [C.52]. 
C.3.8 MDMT: blood 
 Of the 69 studies, 2 examined blood for the presence of MDMT. 
 A total of 39 individuals’ blood samples were examined: 36 patients and 3 controls. 
Among patients, 20 were positive (51%) and 16 were negative. None of the 3 controls 




 A single estimate of 2.0 ng/ml was reported by one study (HPLC-radioimmunoassay) 
[C.52]. 
C.3.9 MDMT; cerebrospinal fluid 
 Of the 69 studies, 4 examined CSF for MDMT. 
 A total of 136 individuals’ CSF samples were assayed: 83 patients and 53 controls. 
Among patients 28 were positive (34%) and 55 were negative. Among controls 12 were 
positive (23%) and 41 were negative. Thus, a total of 40 individuals were positive (29%) 
and 96 were negative. 
 Only one study reported concentrations of MDMT in CSF, in which case the mean 
combined concentrations of DMT and MDMT were approximately 1,400 ng/ml for 
patients and 230 ng/ml for controls with quite large standard deviations (GC-FID) [C.60]. 
 
 The above does not address the analytical methods’ sensitivity and specificity, and 
assumes that all of the data as collected and reported are accurate, either in their detection or 
non-detection of the target analyte(s) or the concentrations observed. However, this is almost 
certainly not the case. As can be seen from Table C.2, almost every study conducted between 
1955-1972 used paper or thin-layer chromatography for detection, quantitation, and confirmation 
of one or more of these compounds. Several studies did use multiple chromatographic conditions 
and detection reagents in attempting to “confirm” their results.  It is well-known, however, that 
paper chromatography is limited in specificity and sensitivity in that spots tend to be diffused 
and the mobility of the compounds of interest is influenced by the presence of other components 
and salts. Thin-layer chromatography is somewhat better but is also susceptible to these same 




chromatographic conditions and very sensitive and moderately specific detection reagents. 
Nevertheless, the criteria for detection relied on Rf values and color reactions relative to 
standards (Table C.2).  There were no data regarding the structure of the detected compounds.  
Much of the literature acknowledged their limitations and qualified results by referring to the 
compounds detected as, for example, “bufotenin-like” [C.4, C.7, C.15].   
 In many studies, large volumes of urine were extracted and concentrated (Table C.1), 
resulting in a final extract less than optimal for such analysis. For example, in order to precipitate 
salts and other compounds, acetone was often used in the final steps of sample purification. 
However, Tanimukai demonstrated that acetone forms adducts with primary amines co-extracted 
in the process leading to formation of compounds that behaved similarly to bufotenin, for 
example, on paper or thin layer chromatography [C.20]. Although there do not seem to be any 
published replications of Tanimukai’s findings, they did lead to modification of many of the 
extraction procedures that were subsequently designed to fractionate tertiary from primary 
amines (Table C.1). 
 As can be seen from Table C.1, the extraction methods employed were predominantly 
classical liquid-liquid extractions with appropriate pH adjustments or the use of ion exchange 
resins or packings. The earliest studies, and especially those extracting large volumes of urine, 
often used a combination of methods in sequence in an attempt to obtain an adequately purified 
and appropriate extract for paper or thin-layer chromatographic analysis. Almost none of these 
studies reported analyte recoveries, however. The most recent methods have all employed ion 





 In addition to methodological complications, misidentifications of compounds may also 
have occurred because both paper and thin layer chromatography using color reagents require a 
somewhat subjective interpretation. For example, Rodnight [C.2] and Siegel et al. [C.12] 
proposed that the substance detected by Bumpus and Paige [C.1] was tryptamine and not HDMT. 
Another potential problem, involving co-injection of extracted indole-ethylamines in GC 
analyses using the solvent methylene chloride, was addressed by Brandt, et al. [C.86]. These 
authors showed that the compounds of interest react with methylene chloride under such 
conditions, forming quaternary salts and analytical artifacts. 
 Some early studies used more than one method for their analyses, increasing the 
likelihood that their identifications were accurate; for example, combining thin layer 
chromatography and gas chromatography with packed column technology. However, the 
resolving power of packed column technology is low and individual “peaks” were often broad 
humps, sometimes several minutes wide. Subsequent studies using capillary chromatography 
have consistently demonstrated that some peaks observed using packed columns were often a 
composite of several compounds. In addition, the flame ionization detector that many studies 
used also lacked specificity. Although these approaches used two different technologies, the 
technologies themselves were relatively non-specific and yielded equivocal results.  
 Some investigators added, or used exclusively, GC with ECD or NP detectors. While 
these detectors added sensitivity --and in the case of NPD a degree of specificity-- they 
continued to rely on Rt and detector response as their identification criteria. No structural data 
were generated.  Other research teams used ultraviolet spectrometry and/or spectrofluorometry to 
detect and quantify the relevant compounds in extracted samples, either directly or after thin-




did not provide data regarding structural identity. For example, Siegel [C.12] demonstrated that 
the fluorescence method used by Franzen and Gross [C.11] did not actually measure a maxima 
from HDMT but instead the tail of the fluorescence spectrum of another compound.  These 
findings bring into question studies that applied these and similar methods. 
 Inconsistent findings in previous research suggest that sensitivity was also an issue. Data 
concerning extraction efficiency and recovery, limits of detection, specificity, reproducibility, 
storage stability, the use of double blind and replicate analyses, and other variables that are now 
basic requirements in assay research are lacking either altogether or in part in earlier studies. At 
best, some early papers point to other references for some of these data.  However, we found 
direct comparisons of methods in either positive or negative studies difficult to conduct.  
 The first applications of mass spectrometry to the detection and quantitation of putative 
endogenous psychedelics in man occurred in 1973. Walker et al. [C.36] and Wyatt et al. [C.37] 
employed an isotope dilution method monitoring two ions to detect and quantitate DMT in 
blood. Soon thereafter, Narasimhachari and Himwich used gas chromatography/mass 
spectrometry with single ion monitoring (m/z 58) to detect DMT from urine extracts [C.38]. 
These latter authors also extracted sufficient material, using TLC for clean-up, to obtain a total 
ion mass spectrum of the detected substance, and demonstrated its identity with authentic DMT.  
These data were the first methodologically credible regarding DMT’s presence in humans. 
Subsequent studies by these and other authors applied different MS capabilities for the detection, 
quantitation, and unequivocal confirmation of DMT and HDMT in humans. In 1974, 
Narasimhachari et al., providing a matching total ion spectrum of an extracted compound, 
reported the unequivocal identification of HDMT from human urine [C.41].  In 1976 Rodnight et 




urine. Other MS techniques matched the retention time and protonated molecule ions (chemical 
ionization MS) for DMT and HDMT in urine [C.50, C.51].  Additional studies detected, 
quantified, and confirmed the identity of DMT, NMT, and HDMT in human blood and urine 
using selected ion monitoring (SIM) of multiple fragment ions (Table C.2). It is important to 
note that MDMT has yet to be unequivocally detected by any MS-based method in blood or 
urine. However, there are two reports of its presence in CSF using GC/MS/SIM [C.53, C.58].  
 Continual improvement in MS technologies has greatly enhanced detection, sensitivity, 
and specificity of analytic studies searching for these compounds; for example, capillary 
chromatography for GC, and more advanced LC-mass spectrometers. This being the case, it is 
encouraging to note that all studies since 1973 using MS methodology have confirmed the 
presence of one or more of these compounds in human body fluids (Table C.2). The most recent 
methods utilize LC/MS/MS which afford analyses and confirmation by several additional 
chemical processes; LC separation and matching of Rt, molecular ion matching, and fragment 
ion presence and ratio matching. This technique also allows for the detection of these compounds 
in the pg/ml range while providing unequivocal mass spectrometric confirmation of structural 
identity. 
 Thus, while many early studies lacked today’s more definitive technology, it is likely that 
many have been confirmed by later MS-based studies. On the other hand, most early studies that 
reported rather high concentrations on these compounds were most likely in error. 
C.4 Discussion and Conclusions 
 The answer to the question, “Are the tryptamine psychedelic substances DMT, HDMT 
and MDMT present in the human body?” is most likely “Yes.” We believe that the 




HDMT are indeed endogenous and can be measured in human body fluids. The evidence is less 
compelling for MDMT where the only two MS-based positive studies--in CSF--were performed 
by the same research group. There is no mass spectral data on detection of MDMT in blood or 
urine. Thus, further studies are necessary to determine whether MDMT exists in humans. 
Similarly, there are no data on the possible presence of HDMT in CSF. This too requires 
examination. 
 With respect to the paucity of data regarding endogenous MDMT, it should also be noted 
that HDMT is both a metabolite of and precursor for MDMT. The relationship of these two 
compounds may help explain why HDMT is so much more frequently detected than MDMT.  
Future studies will help explicate this relationship. 
 As to the question, “Were the analytical methodologies and the criteria for compound 
identification adequate?”, the answer is less certain. Undoubtedly, some studies misidentified the 
target compounds or, at the minimum, greatly overestimated their concentrations.  
 Are they of dietary origin? Many early studies attempted to determine if diet or gut 
bacteria were responsible for positive results.  Sterilization of the gut with antibiotics or feeding 
subjects special diets had no effect on these studies’ results. In addition, no evidence suggested 
that medication(s) played a role.  More recently, however, Karkkainen et al. [C.68] isolated 
significant quantities of HDMT from stool samples, and hypothesized that HDMT may be 
synthesized by cells of the intestinal epithelium or the kidney, but not by gut flora.  
 When are these compounds produced? The very small numbers of studies that have 
looked for diurnal, circadian, or ultradian variations in levels of DMT or HDMT in humans have 
been negative. This may be due, in part, to too infrequent sampling times and inadequate assay 




human urine suggest that measurable concentrations occur only intermittently [C.50]. The same 
is apparently true for HDMT [C.64]. There are no comparable data available for MDMT. The 
two DMT studies cited were conducted in urine only and such analyses are probably best 
conducted in blood. They do stand, however, as examples of one of the possible further 
complications in understanding the source, role and function of these compounds. 
 Where in the human body are they synthesized? The tissue source or sources of these 
compounds in humans remains unknown and, that being the case, we should not assume that 
monitoring blood, urine, or CSF will answer this question. DMT synthesis has been proposed to 
occur in adrenal and lung, where high levels of the enzyme responsible for its synthesis--indole-
N-methyltransferase (INMT)--have been reported [C.96, C.97]. While these studies did not 
demonstrate high INMT levels in brain, the active transport of DMT across the blood-brain 
barrier [C.98] suggests that peripheral synthesis may nevertheless affect central function. In 
addition, the mapping of INMT sites thus far has been based solely on INMT mRNA studies 
which only establish where active enzyme translation is occurring.  However, recent studies by 
Cozzi et al.[C.99], using a fluorescent antibody to INMT and confocal microscopy, have 
identified INMT in spinal cord, brain, retina, and pineal, and suggest the possibility of applying 
other powerful molecular biology tools and methods for mapping the location and characterizing 
the regulation of the endogenous psychedelic pathway. Their findings suggest that INMT may be 
an inducible enzyme. These molecular biological approaches, in combination with advances in 
assay methodology, may help finally characterize the biochemistry and physiology of these 
compounds in humans. 
 The next questions, “Can we influence the detection of endogenous psychedelics in 




these substances influence their detectabilty?” “Have the precursors and/or metabolites of these 
compounds been adequately monitored?” require synthesizing several parallel lines of evidence. 
In humans, only a very small percentage of exogenously administered DMT is excreted in urine 
as the parent compound [C.88]. This is also true for HDMT [C.100] and MDMT [C.101]. 
Despite this fact, every cited study monitored, without exception, only the parent compounds 
themselves in the various biological fluids examined. These compounds all have a very short 
half-life—a few minutes—and blood levels are undetectable in less than an hour after 
administration. This rapid metabolism is due to their being excellent substrates for MAO-A.  
This enzyme’s action on the psychedelic tryptamines results in the formation of their 
corresponding indoleacetic acids, which are indistinguishable from these same acids resulting 
from other better-known sources, such as tryptamine and serotonin. Several studies attempted to 
maximize detection of these substances by treating subjects with MAO inhibitors such as 
tranylcypromine and phenelzine (Table C.3). In most cases, this did result in higher 
concentrations of the target compounds. Nevertheless, even with significant MAO inhibition, the 
concentrations of parent compounds remained quite small. This observation has, perhaps, a ready 
explanation: the other metabolic pathways for DMT, MDMT, and HDMT. 
 Recognition and understanding of these compounds’ pathways for degradation may 
afford an approach to circumventing the low concentrations of the parent compounds observed 
even after MAO inhibition.  Sitaram et al. [C.89-C.91] have shown that, in MAO inhibited rats, 
metabolism of these psychoactive tryptamines is shifted away from MAO-A and indoleacetic 
acid formation to the N-oxidase and the respective N-oxides. However, no studies have yet 
pretreated humans with MAO inhibitors and measured the parent compounds and their 




indoleacetic acid, retains the original structure of the parent molecule, permitting a cumulative 
association. As a proof of concept, we, have measured blood and urine levels of DMT and its N-
oxide (C.1.5, Figure C.1) in humans administered a botanical preparation of DMT and MAO-A 
inhibiting harmala alkaloids—the Amazonian brew ayahuasca [C.102, C.103].  Concentrations 
of the N-oxide of DMT in these subjects were 3-4 times greater in blood, and 20 times greater in 
urine, than DMT itself. Therefore, monitoring the N-oxide metabolites rather than the parent 
compounds alone in MAO-inhibited humans may provide a substantial advantage in detecting 
and quantitating the endogenous psychedelic compounds.   
 Several of the studies reviewed did examine samples for the corresponding NMT, which 
is both a precursor for and a metabolite of the three endogenous psychedelics (NMT, HNMT, 
MNMT). However, in humans administered ayahuasca NMT was only intermittently detected in 
blood and urine and concentrations were quite low (pg/ml)[C.102, C.103]. This also may be the 
result of a shift in metabolism of DMT to the N-oxide after MAO inhibition and suggests that 
monitoring NMT in vivo may not be necessary or possible.  Nonetheless, several of the reviewed 
studies suggested that the corresponding NMT was detected, however (Table C.3). That data 
must now also be in question.  
 DMT-N-oxide is neither a substrate for MAO-A nor for N-demethylases. Since similar 
metabolic pathways exist for HDMT and MDMT, we suggest that MAO inhibition in humans 
will enhance detection and quantitation of these compounds in the periphery, especially if the N-
oxide metabolites are monitored.   
 Thus, we can respond to the questions, “Is monitoring these compounds in biological 
samples such as CSF, blood and/or urine the best, or even most practical way to determine their 




compounds in humans?”  Data regarding their peripheral dynamics—concentrations, circadian 
variation, and metabolism, as assessed by rigorous analytic methods applied to biological 
samples represent the most accessible approach to beginning to determine their possible role in 
human psychophysiology and should be pursued. 
 Our last question, “Where does the research on endogenous psychedelics go from here?” 
One avenue for future studies concerns the endogenous nature of MDMT. This review has 
illustrated the convincing evidence that DMT and HDMT are endogenous in humans. However, 
MDMT has not been reported in human blood or urine but is apparently present in CSF. 
However, CSF has not been examined for the presence of HDMT.  We propose that future 
studies of CSF, blood (including whole blood where higher concentrations may be observed) and 
urine monitor all three compounds and their N-oxides using superior, fully validated mass 
spectrometric methodology. Pretreatment of study subjects with an MAO inhibitor should 
optimize results and may prove critical to such studies. A technical issue regarding HDMT 
analysis also must be considered in future studies. Assays for this compound should include an 
enzyme hydrolysis step to free conjugates that may be formed from both the parent compound 
and it’s N-oxide. 
 Another area for future research concerns assay sensitivity. We believe it is necessary to 
improve sensitivity of assays of the parent compounds to 1.0 pg/ml or less. Given the possible 
intermittent presence of these compounds in the periphery, blood and urine analyses may require 
more frequent sampling and longer collection times.    
 The search for endogenous psychedelic tryptamines should also turn towards other 
human tissues than blood, urine and CSF; that is, solid organs such as adrenal, brain, lung, 




tools. The combination of assaying relevant compounds with cell and molecular biology 
approaches will provide the most detailed possible assessment of the location(s) of synthesis and, 
ultimately, the role of these compounds in human physiology. 
 For example, mapping of INMT and its presence within certain cell types and locations, 
should reveal its intracellular distribution and possible associations with various receptors. The 
introduction of an INMT knockout mouse to the research effort could greatly assist in 
understanding the role of this enzyme and, by inference, the endogenous psychedelics. With 
these tools in hand, the research that can be conducted may finally provide us an answer to the 
question, “Why do humans produce endogenous psychedelics?” The research thus far is limited 
but there are many possibilities awaiting further inquiry. 
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Agreement shall not be affected or impaired thereby.  
 
10. The failure of either party to enforce any term or condition of this Agreement shall not constitute a waiver of 
either party's right to enforce each and every term and condition of this Agreement. No breach under this 
agreement shall be deemed waived or excused by either party unless such waiver or consent is in writing signed 
by the party granting such waiver or consent. The waiver by or consent of a party to a breach of any provision of 
this Agreement shall not operate or be construed as a waiver of or consent to any other or subsequent breach by 
such other party.  
 
11. This Agreement may not be assigned (including by operation of law or otherwise) by you without WILEY's 
prior written consent.  
 
12. Any fee required for this permission shall be non-refundable after thirty (30) days from receipt.  
 
13. These terms and conditions together with CCC’s Billing and Payment terms and conditions (which are 
incorporated herein) form the entire agreement between you and WILEY concerning this licensing transaction 
and (in the absence of fraud) supersedes all prior agreements and representations of the parties, oral or written. 
This Agreement may not be amended except in writing signed by both parties. This Agreement shall be binding 
upon and inure to the benefit of the parties' successors, legal representatives, and authorized assigns.  
 
14. In the event of any conflict between your obligations established by these terms and conditions and those 
established by CCC’s Billing and Payment terms and conditions, these terms and conditions shall prevail.  
 
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) the license details 
provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) 
CCC’s Billing and Payment terms and conditions.  
 
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was misrepresented 
during the licensing process.  
 
17. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, 
USA, without regards to such state’s conflict of law rules. Any legal action, suit or proceeding arising out of or 
relating to these Terms and Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of America and each party hereby 
consents and submits to the personal jurisdiction of such court, waives any objection to venue in such court and 
consents to service of process by registered or certified mail, return receipt requested, at the last known address 
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All research articles published in Wiley Open Access journals are fully open access: immediately freely available 
to read, download and share. Articles are published under the terms of the Creative Commons Attribution Non 
Commercial License. which permits use, distribution and reproduction in any medium, provided the original work 
is properly cited and is not used for commercial purposes. The license is subject to the Wiley Open Access terms 




Wiley Open Access articles are protected by copyright and are posted to repositories and websites in 
accordance with the terms of the Creative Commons Attribution Non Commercial License. At the time of deposit, 
Wiley Open Access articles include all changes made during peer review, copyediting, and publishing. 
Repositories and websites that host the article are responsible for incorporating any publisher-supplied 
amendments or retractions issued subsequently.  
Wiley Open Access articles are also available without charge on Wiley's publishing platform, Wiley Online 
Library or any successor sites.  
 
Use by non-commercial users  
 
For non-commercial and non-promotional purposes individual users may access, download, copy, display and 
redistribute to colleagues Wiley Open Access articles, as well as adapt, translate, text- and data-mine the 
content subject to the following conditions:  
  The authors' moral rights are not compromised. These rights include the right of "paternity" (also known as 
"attribution" - the right for the author to be identified as such) and "integrity" (the right for the author not to have 
the work altered in such a way that the author's reputation or integrity may be impugned).  
  Where content in the article is identified as belonging to a third party, it is the obligation of the user to ensure 
that any reuse complies with the copyright policies of the owner of that content.  
  If article content is copied, downloaded or otherwise reused for non-commercial research and education 
purposes, a link to the appropriate bibliographic citation (authors, journal, article title, volume, issue, page 
numbers, DOI and the link to the definitive published version on Wiley Online Library) should be maintained. 
Copyright notices and disclaimers must not be deleted.  
  Any translations, for which a prior translation agreement with Wiley has not been agreed, must prominently 
display the statement: "This is an unofficial translation of an article that appeared in a Wiley publication. The 
publisher has not endorsed this translation."  
Use by commercial "for-profit" organisations  
 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further explicit 
permission from Wiley and will be subject to a fee. Commercial purposes include:  
  Copying or downloading of articles, or linking to such articles for further redistribution, sale or licensing;  
  Copying, downloading or posting by a site or service that incorporates advertising with such content;  
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  Use for the purposes of monetary reward by means of sale, resale, licence, loan, transfer or other form of 
commercial exploitation such as marketing products  
  Print reprints of Wiley Open Access articles can be purchased from: corporatesales@wiley.com  
 
Other Terms and Conditions:  
 




UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT AND 
THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF YOUR OBLIGATIONS AS 
SET FORTH IN THIS AGREEMENT.  
 
v1.7  
If you would like to pay for this license now, please remit this license along with your payment made 
payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the 
license date. Payment should be in the form of a check or money order referencing your account number 
and this invoice number RLNK500754604. 
Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow 
instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink Customer Support: 
customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your 
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